

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16353 A1

(51) International Patent Classification⁷: C07D 405/12,
419/12, 417/12, A61K 31/34, 31/445, A61P 37/00, 29/00

Bath Road, Slough, Berkshire SL1 3WE (GB). MELLOR,
Sarah, Louise [GB/GB]; Celltech R & D Limited, 208
Bath Road, Slough, Berkshire SL1 3WE (GB).

(21) International Application Number: PCT/GB01/03721

(22) International Filing Date: 16 August 2001 (16.08.2001)

(74) Agent: MCKINNEY, Victoria; Celltech R & D Limited,
208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0020341.4 17 August 2000 (17.08.2000) GB
0111471.9 11 May 2001 (11.05.2001) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(71) Applicant (*for all designated States except US*): CELL-
TECH R & D LIMITED [GB/GB]; 208 Bath Road,
Slough, Berkshire SL1 3WE (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): OWEN, David,
Alan [GB/GB]; Celltech R & D Limited, 208 Bath Road,
Slough, Berkshire SL1 3WE (GB). HAUGHAN, Alan,
Findlay [GB/GB]; Celltech R & D Limited, 208 Bath
Road, Slough, Berkshire SL1 3WE (GB). BATTY, Dun-
can [GB/GB]; Celltech R & D Limited, 208 Bath Road,
Slough, Berkshire SL1 3WE (GB). DRAFFAN, Alistair,
George [GB/GB]; Celltech R & D Limited, 208 Bath
Road, Slough, Berkshire SL1 3WE (GB). KENDALL,
Hannah, Jayne [GB/GB]; Celltech R & D Limited, 208

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

(57) Abstract: Compounds of formula (1) are described, wherein q is zero or the integer 1, 2 or 3; R which when present may be attached to any available carbon or nitrogen atom of the bicyclic heteroaromatic ring of formula (1) is an atom or group $-L^3(Alk^3)_wL^4(R^8)_u$; X is an O atom or a $S(O)_m$ atom or group in which m is zero or the integer 1 or 2 or an NR group; Y is a N atom or a CR^{1a} group in which R^{1a} is a group R or a group R^1 ; R^1 which may be on any available carbon atom of the bicyclic heteroaromatic ring of formula (1) is a hydrogen atom or a group $-Alk^1L^1CyAlk^4L^2D$; provided that at least one but not both of R^1 and R^{1a} is the group $-Alk^1L^1CyAlk^4L^2D$. The compounds are potent inhibitors of the interaction between CCR-3 and its chemokine ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders in which inhibition of this interaction can have a beneficial effect.

BEST AVAILABLE COPY

WO 02/16353 A1

BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND
INFLAMMATORY DISORDERS

This invention relates to a series of bicyclic heteroaromatic derivatives, to
5 compositions containing them, to processes for their preparation, and to their
use in medicine.

Over the last few years it has become increasingly clear that chemokines
(chemotactic cytokines) play a key role in the recruitment and activation of a
10 variety of cell types in inflammatory processes, for example recruitment of
eosinophils in the tissue eosinophilia that is a feature of a number of
pathological conditions including asthma, rhinitis, eczema and parasitic
infections [Schwarz, M. K. and Wells, T. N. C., Curr. Opin. Chem. Biol., 1999,
3, 407-17; Bousquet, J. *et al*, N. Eng. J. Med., 1990, 323, 1033-39; Kay, A. B.
15 and Corrigan, C. J., Br. Med. Bull., 1992, 48, 51-64].

Chemokines are released by a wide variety of cells to attract and activate,
among other cell types, macrophages, T and B lymphocytes, eosinophils,
basophils and neutrophils [Luster, New Eng. J. Med., 1998, 338, 436-45;
20 Rollins, Blood, 1997, 90, 909-28]. To date almost 40 human chemokines
have been well characterised [Schwarz, M. K., *ibid*; Wells, T. N. C. *et al*,
Trends Pharmacol Sci, 1998, 19, 376-380] and they have been classified into
two major classes, CXC and CC, depending on whether the first two
cysteines in the amino acid sequence are separated by a single amino acid
25 (CXC) or are adjacent (CC). Members of two additional classes, C
chemokines (lymphotactin-1 and lymphotactin-2) and a CX3C chemokine
(fractalkine) have also been identified. It was initially thought that CXC
chemokines, such as IL-8 (a neutrophil attractant), were associated with
acute inflammation whilst CC chemokines were associated with chronic
30 inflammatory diseases such as asthma, arthritis and atherosclerosis.
However it is now known that members of both classes are involved in both
chronic and acute inflammation.

In general the CXC chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activating protein (MGSA) are chemotactic primarily for neutrophils and T lymphocytes, whereas CC chemokines such as RANTES (regulation-upon-activation,
5 normal T expressed and secreted), MIP-1 α , MIP-1 β , the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, MCP-4, MCP-5) and the eotaxins (-1, -2 and -3) are chemotactic for macrophages, T lymphocytes, eosinophils, dendritic cells and basophils.

10 The chemokines bind to specific cell-surface receptors. Seventeen mammalian receptors have been reported to date [Schwarz, M. K. *ibid*], all of which are seven-transmembrane-spanning G-protein coupled receptors. The ligand binding characteristics of these receptors have been identified, for example the ligands for CCR-1 are RANTES, MIP-1 α and MCP-3 whilst
15 those for CCR-2 are MCP-1, 2, 3, 4 and 5.

Chemokines and their receptors have been implicated as important mediators of inflammatory, infectious, and immunoregulatory diseases, as well as autoimmune pathologies such as rheumatoid arthritis and
20 atherosclerosis. For example, in asthma eosinophil accumulation and activation in response to the chemokines RANTES, eotaxin and MCP-3 is associated with damage to bronchial epithelium and airway hyperresponsiveness to mediators of bronchoconstriction. Of these three chemokines eotaxin alone is selectively chemotactic for eosinophils [Griffith-
25 Johnson, D. A. *et al*, Biochem. Biophys. Res. Commun., 1993, 197, 1167; Jose, J. P. *et al*, Biochem. Biophys. Res. Commun., 1994, 207, 788]. Specific eosinophil accumulation was observed at the site of administration of eotaxin via either the intradermal, intraperitoneal or aerosol inhalation route [Griffith-Johnson, *ibid*; Jose, P. J. *et al*, J. Exp. Med., 1994, 179, 881-7; Rothenberg,
30 M. E. *et al*, J. Exp. Med., 1995, 181, 1211; Ponath, P. D., J. Clin. Invest., 1996, 97, 604-12].

Current therapies for eosinophil-related disorders such as bronchial asthma include glucocorticoids (dexamethasone, methprednisolone and

hydrocortisone) [Schleimer, R. P. *et al*, Am. Rev. Respir. Dis., 1990, 141, 559]. The glucocorticoids are believed to inhibit IL-5 and IL-3 mediated eosinophil survival in these diseases. It is known, however, that prolonged use of glucocorticoids can lead to undesirable side effects such as glaucoma, osteoporosis and growth retardation. There is thus a need for alternate means of treating eosinophil mediated disorders.


It has become clear that the CCR-3 chemokine receptor plays a pivotal role in the recruitment of eosinophils to sites of allergic inflammation and in subsequently activating these cells in response to RANTES, eotaxin, MCP-3 and MCP-4 [Ponath, P. D. *et al*, J. Exp. Med., 1996, 183, 2437-48]. These chemokine ligands for CCR-3 induce a rapid increase in intracellular calcium concentration, increased expression of cellular adhesion molecules, cellular degranulation and the promotion of eosinophil migration. The release of lipid mediators, cytotoxic proteins, oxygen metabolites and cytokines by eosinophils upon activation all have the potential to produce a pathophysiological response. The CCR-3 receptor is expressed on the surface of eosinophils, T-cells (subtype Th-2) and to a lesser extent basophils and mast cells and is the only known chemokine receptor for eotaxin. It has been shown that pretreatment with an anti-CCR-3 monoclonal antibody completely inhibits eosinophil chemotaxis to eotaxin, RANTES and MCP-3 [Heath, H. *et al*, J. Clin. Invest., 1997, 99, 178-84]. The restricted expression of CCR-3 on eosinophils and T-cells may be responsible for the selective recruitment of eosinophils and Th-2 T-cells in allergic inflammation.

Mammalian cytomegaloviruses, herpesviruses and poxviruses have been shown to express, in infected cells, proteins with the binding properties of chemokine receptors (Wells and Schwartz, Curr. Opin. Biotech., 1997, 8, 741-48). Human CC chemokines (e.g. RANTES and MCP-3) can cause rapid mobilization of calcium via these virally encoded receptors, the expression of which may allow for infection by permitting subversion of the normal immune system surveillance and response to infection. Additionally human chemokine receptors (e.g. CXCR4, CCR2, CCR3, CCR5 and CCR8) can act

as co-receptors for the infection of mammalian cells by microbes such as the human immunodeficiency virus (HIV).

Accordingly there is a great need for agents that modulate the ability of chemokines to bind to chemokine receptors, particularly agents that block the ability of RANTES, eotaxin, MCP-3 and MCP-4 to bind to CCR-3, thus preventing the recruitment of eosinophils and so providing a method of treatment for eosinophil-mediated inflammatory diseases. We have found a class of bicyclic heteroaromatic derivatives that are potent inhibitors of the interaction between CCR-3 and its chemokine ligands. The compounds are thus of use in medicine, for example in the prophylaxis and treatment of immune or inflammatory disorders as described hereinafter.

Thus according to one aspect of the invention we provide a compound of formula (1):



wherein:

q is zero or the integer 1, 2 or 3;

R which when present may be attached to any available carbon or nitrogen atom of the bicyclic heteroaromatic ring of formula (1) is an atom or group – $L^3(Alk^3)_wL^4(R^8)_u$ in which L^3 and L^4 which may be the same or different is each a covalent bond or a linker atom or group, w is zero or the integer 1, u is the integer 1, 2 or 3, Alk^3 is an optionally substituted aliphatic or heteroaliphatic chain and R^8 is a hydrogen or halogen atom or a group selected from alkyl, -OR⁹ [where R⁹ is a hydrogen atom or an optionally substituted alkyl group], -SR⁹, -NR⁹R¹⁰, [where R¹⁰ is as just defined for R⁹ and may be the same or different], -NO₂, -CN, -CO₂R⁹, -OCO₂R⁹, -CONR⁹R¹⁰, -OCONR⁹R¹⁰, -CSNR⁹R¹⁰, -COR⁹, -OCOR⁹, -N(R⁹)COR¹⁰, -N(R⁹)CSR¹⁰, -SO₂N(R⁹)(R¹⁰), -


5

$N(R^9)SO_2R^{10}$, $-N(R^9)CON(R^{10})(R^{11})$, [where R^{11} is a hydrogen atom or an optionally substituted alkyl group], $-N(R^9)CSN(R^{10})(R^{11})$, $-N(R^9)SO_2N(R^{10})(R^{11})$ or an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group provided that when u is zero and each of L^3 and L^4 is a covalent bond then u is the integer 1; or when q is the integer 2 or 3 and two R groups are attached to adjacent carbon atoms of the heteroaromatic ring of formula (1) these may be joined together with the heteroaromatic ring carbon atoms to form an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;

X is an O atom or a $S(O)_m$ atom or group in which m is zero or the integer 1 or 2 or an NR group;

Y is a N atom or a CR^{1a} group in which R^{1a} is a group R or a group R^1 ; R^1 which may be on any available carbon atom of the bicyclic heteroaromatic ring of formula (1) is a hydrogen atom or a group $-Alk^1L^1CyAlk^2L^2D$ in which Alk^1 is an optionally substituted C_{1-3} alkyl group, Alk^2 is an optionally substituted aliphatic or cycloaliphatic group, L^1 is a $-CON(R^5)-$, $-N(R^5)CO-$, $-SO_2N(R^5)-$ or $-N(R^5)SO_2-$ group in which R^5 is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group, L^2 is a covalent bond or an $-O-$ atom or $-S(O)_n-$ atom or group in which n is zero or the integer 1 or 2 or $-N(R^7)-$ group in which R^7 is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group, D is an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group and Cy is an optionally substituted heterocycloaliphatic ring of formula (A) or (B):

30



in which

- a indicates the point of attachment of any available ring carbon in the ring Cy to the group L^1 , b indicates the point of attachment to Alk^2 , s and t which may be the same or different is each zero or the integer 1 or 2, provided that $s + t$ is the integer 1, 2, 3 or 4, R^6 is an optionally substituted alkyl group and X is a pharmaceutically acceptable counterion;
- provided that at least one but not both of R^1 and R^{1a} is the group $-Alk^1L^1CyAlk^2L^2D$;
- and the salts, solvates, hydrates, N-oxides thereof.

It will be appreciated that certain compounds of formula (1) may exist as geometric isomers (E or Z isomers) The compounds may also have one or more chiral centres, and exist as enantiomers or diastereomers. The invention is to be understood to extend to all such geometric isomers, enantiomers, diastereomers and mixtures thereof, including racemates. Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless stated or shown otherwise. In addition, compounds of formula (1) may exist as tautomers, for example keto ($CH_2C=O$) – enol ($CH=CHOH$) tautomers. Formula (1) and the formulae hereinafter are intended to represent all individual tautomers and mixtures thereof, unless stated otherwise.

In the compounds of the invention as represented by formula (1) and the more detailed description hereinafter certain of the general terms used in relation to substituents are to be understood to include the following atoms or groups unless specified otherwise.

Thus as used herein the term "alkyl", whether present as a group or part of a group includes straight or branched C_{1-10} alkyl groups, for example C_{1-6} alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl groups and C_{3-10} cycloalkyl groups, for example C_{3-6} cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups. Similarly, the terms "alkenyl" or "alkynyl" are intended to mean straight or branched C_2 -

$_{10}$ alkenyl or C_{2-10} alkynyl groups such as C_{2-6} alkenyl or C_{2-6} alkynyl groups such as $-CHCH_2$, $-CHCHCH_3$, $-CH_2CHCHCH_3$, $-CCH$, $-CH_2CCH$ and $-CH_2CCCH_3$ groups. Optional substituents present on those groups include those optional substituents mentioned hereinafter in relation to optionally substituted aliphatic groups.

The term "halogen atom" is intended to include fluorine, chlorine, bromine or iodine atoms.

The term "haloalkyl" is intended to include the alkyl groups just mentioned substituted by one, two or three of the halogen atoms just described. Particular examples of such groups include $-CF_3$, $-CCl_3$, $-CHF_2$, $-CHCl_2$, $-CH_2F$, and $-CH_2Cl$ groups.

The term "alkoxy" as used herein is intended to include straight or branched C_{1-10} alkoxy for example C_{1-6} alkoxy such as methoxy, ethoxy, n-propoxy, i-propoxy and t-butoxy. "Haloalkoxy" as used herein includes any of those alkoxy groups substituted by one, two or three halogen atoms as described above. Particular examples include $-OCF_3$, $-OCCl_3$, $-OCHF_2$, $-OCHCl_2$, $-OCH_2F$ and $-OCH_2Cl$ groups.

As used herein the term "alkylthio" is intended to include straight or branched C_{1-10} alkylthio, e.g. C_{1-6} alkylthio such as methylthio or ethylthio groups.

The term "aliphatic group" is intended to include optionally substituted straight or branched C_{1-10} alkyl, e.g. C_{1-6} alkyl, C_{2-10} alkenyl e.g. C_{2-6} alkenyl or C_{2-10} alkynyl e.g. C_{2-6} alkynyl groups.

The term "heteroaliphatic group" is intended to include the optionally substituted aliphatic groups just described but with each group additionally containing one, two, three or four heteroatoms or heteroatom-containing groups. Particular heteroatoms or groups include atoms or groups L^5 where L^5 is a linker atom or group. Each L^5 atom or group may interrupt the aliphatic

group, or may be positioned at its terminal carbon atom to connect the group to an adjoining atom or group. Particular examples of suitable L^5 atoms or groups include -O- or -S- atoms or -C(O)-, -C(O)O-, -C(S)-, -S(O), -S(O)₂-, -N(R¹⁷)- [where R¹⁷ is a hydrogen atom or an alkyl group], -N(R¹⁷)N(R¹⁷)-, -N(R¹⁷)O-, -CON(R¹⁷)-, -OC(O)N(R¹⁷)-, -CSN(R¹⁷)-, -N(R¹⁷)CO-, -N(R¹⁷)C(O)O-, -N(R¹⁷)CS-, -S(O)₂N(R¹⁷)-, -N(R¹⁷)S(O)₂-, -N(R¹⁷)CON(R¹⁷)-, -N(R¹⁷)CSN(R¹⁷)-, or -N(R¹⁷)SO₂N(R¹⁷)- groups. Where the linker group contains two R¹⁷ substituents, these may be the same or different.

Particular examples of aliphatic groups include optionally substituted -CH₃, -CH₂CH₃, -CH(CH₃)₂, -(CH₂)₂CH₃, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃, -(CH₂)₄CH₃, -(CH₂)₅CH₃, -CHCH₂, -CHCHCH₃, -CH₂CHCH₂, -CHCHCH₂CH₃, -CH₂CHCHCH₃, -(CH₂)₂CHCH₂, -CCH, -CCCH₃, -CH₂CCH, -CCCH₂CH₃, -CH₂CCCH₃, or -(CH₂)₂CCH groups. Where appropriate each of said groups may be optionally interrupted by one, two, three or more atoms and/or groups L^5 to form an optionally substituted heteroaliphatic group. Particular examples include optionally substituted - L^5 CH₃, -CH₂ L^5 CH₃, - L^5 CH₂CH₃, - L^5 CH₂CHCH₂, - L^5 CH₂CCH, -CH₂ L^5 CH₂CH₃, - L^5 CH₂ L^5 CH₃, -(CH₂)₂ L^5 CH₃, - L^5 (CH₂)₂CH₃ and -(CH₂)₂ L^5 CH₂CH₃ groups.

20

The optional substituents which may be present on aliphatic or heteroaliphatic groups include one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, or alkoxy, hydroxy (-OH), thiol (-SH), alkylthio, amino (-NH₂), substituted amino, optionally substituted C₆₋₁₂aryl amino, -CN, -CO₂H, -CO₂R¹² (where R¹² is an alkyl group), -SO₃H, -SOR¹², -SO₂R¹², -SO₃R¹², -OCO₂R¹², -C(O)H, -C(O)R¹², -OC(O)R¹², -C(S)R¹², -C(O)N(R¹³)(R¹⁴) (where R¹³ and R¹⁴, which may be the same or different is each a hydrogen atom or an alkyl group), -OC(O)N(R¹³)(R¹⁴), -N(R¹³)C(O)R¹⁴, -CSN(R¹³)(R¹⁴), -N(R¹³)C(S)(R¹⁴), -SO₂N(R¹³)(R¹⁴), -N(R¹³)SO₂R¹⁴, -N(R¹³)C(O)N(R¹⁴)(R¹⁵) (where R¹⁵ is a hydrogen atom or an alkyl group), -N(R¹³)C(S)N(R¹⁴)(R¹⁵), -N(R¹³)SO₂N(R¹⁴)(R¹⁵), or an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group. Substituted amino

30

groups include -NHR^{12} and $\text{-N(R}^{12})(\text{R}^{13})$ groups. Optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic and heteroaromatic groups include those groups described hereinafter.

- 5 The term optionally substituted aliphatic or heteroaliphatic chain is intended to include those optionally substituted aliphatic and heteroaliphatic groups as just described where a terminal hydrogen atom is replaced by a covalent bond to give a divalent chain.
- 10 The term "cycloaliphatic group" is intended to include optionally substituted C_{3-10} cycloaliphatic groups. Particular examples include optionally substituted C_{3-10} cycloalkyl, e.g. C_{3-8} cycloalkyl or C_{3-10} cycloalkenyl, e.g. C_{3-8} cycloalkenyl groups.
- 15 The term "heterocycloaliphatic group" is intended to include optionally substituted C_{3-10} heterocycloaliphatic groups. Particular examples include optionally substituted C_{3-10} heterocycloalkyl, e.g. C_{3-7} heterocycloalkyl, or C_{3-10} heterocycloalkenyl, e.g. C_{3-7} heterocycloalkenyl groups, each of said groups containing one, two, three or four heteroatoms or heteroatom-containing
- 20 groups L^5 as just defined.

The term "polycycloaliphatic group" is intended to include optionally substituted C_{7-10} bi- or tricycloalkyl or C_{7-10} bi- or tricycloalkenyl groups. The term "heteropolycycloaliphatic group" is intended to include the optionally

- 25 substituted polycycloaliphatic groups just described, but with each group additionally containing one, two, three or four L^5 atoms or groups.

Particular examples of cycloaliphatic, polycycloaliphatic, heterocycloaliphatic and heteropolycycloaliphatic groups include optionally substituted cyclopropyl,

- 30 cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutenyl, cyclopentenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantyl, norbornyl, norbornenyl, tetrahydrofuranyl, tetrahydropyranyl, pyrroline, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, pyrrolidinone, oxazolidinyl,

oxazolidinone, dioxolanyl, e.g. 1,3-dioxolanyl, imidazoliny, e.g. 2-imidazoliny, imidazolidiny, pyrazoliny, e.g. 2-pyrazoliny, pyrazolidiny, thiazoliny, thiazolidiny, pyran, e.g. 2- or 4-pyran, piperidiny, piperidinone, 1,4-dioxanyl, morpholiny, morpholinone, 1,4-dithian, thiomorpholiny, piperaziny, 1,3,5-trithian, oxaziny, e.g. 2H-1,3-, 6H-1,3-, 6H-1,2-, 2H-1,2- or 4H-1,4- oxaziny, 1,2,5-oxathiaziny, isoxaziny, e.g. o- or p-isoxaziny, oxathiaziny, e.g. 1,2,5 or 1,2,6-oxathiaziny, or 1,3,5-oxadiaziny or succinimidyl groups.

10 Cycloaliphatic and polycycloaliphatic groups may be linked to the remainder of the compound of formula (1) by any available ring carbon atom. Heterocycloaliphatic and heteropolycycloaliphatic groups may be linked to the remainder of the compound of formula (1) by any available ring carbon or, where available, ring nitrogen atom.

15

The optional substituents which may be present on the cycloaliphatic, polycycloaliphatic, heterocycloaliphatic or heteropolycycloaliphatic groups include one, two, three or more optionally substituted alkyl groups and/or optional substituents as described above in relation to aliphatic or heteroaliphatic groups.

20

The terms "aromatic group" and "aryl group" are intended to include for example optionally substituted monocyclic or bicyclic fused ring C₆₋₁₂ aromatic groups, such as phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups. Each of these aromatic groups may be optionally substituted by one, two, three or more R¹⁹ atoms or groups as defined below.

25

The terms "heteroaromatic group" and "heteroaryl group" are intended to include for example optionally substituted C₁₋₉ heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered

30

heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example eight- to thirteen-membered fused-ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

The aromatic and heteroaromatic groups may be attached to the remainder of the compound of formula (1) by any carbon or hetero e.g. nitrogen atom as appropriate.

10

Particular examples of heteroaromatic groups of these types include pyrrolyl, furyl, thienyl, imidazolyl, N-C₁₋₆alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, benzothienyl, benzotriazolyl, indolyl, indolinyl, isoindolyl, indazolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzopyranyl, [3,4-dihydro]benzopyranyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]-pyridyl, quinolinyl, isoquinolinyl, phthalazinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl or 5,6,7,8-tetrahydroisoquinolinyl.

Optional substituents which may be present on the aromatic or heteroaromatic groups include one, two, three or more substituents, each selected from an atom or group R¹⁹ in which R¹⁹ is -R^{19a} or -Alk⁴(R^{19a})_f, where R^{19a} is a halogen atom, or an amino (-NH₂), substituted amino, nitro, cyano, amidino, hydroxyl (-OH), substituted hydroxyl, formyl, carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol, -COR²⁰ [where R²⁰ is an -Alk⁴(R^{19a})_f, aryl or heteroaryl group], -CSR²⁰, -SO₃H, -SOR²⁰, -SO₂R²⁰, -SO₃R²⁰, -SO₂NH₂, -SO₂NHR²⁰, SO₂N(R²⁰)₂, -CONH₂, -CSNH₂, -CONHR²⁰, -CSNHR²⁰, -CON(R²⁰)₂, -CSN(R²⁰)₂, -N(R²¹)SO₂R²⁰, [where R²¹ is a hydrogen atom or an alkyl group] -N(SO₂R²⁰)₂, -N(R²¹)SO₂NH₂, -N(R²¹)SO₂NHR²⁰, -

$N(R^{21})SO_2N(R^{20})_2$, $-N(R^{21})COR^{20}$, $-N(R^{21})CONH_2$, $-N(R^{21})CONHR^{20}$, $-$
 $N(R^{21})CON(R^{20})_2$, $-N(R^{21})CSNH_2$, $-N(R^{21})CSNHR^{20}$, $-N(R^{21})CSN(R^{20})_2$, $-$
 $N(R^{21})CSR^{20}$, $-N(R^{21})C(O)OR^{20}$, $-SO_2NHet^1$ [where $-NHet^1$ is an optionally
substituted C_{6-7} cyclicamino group optionally containing one or more other $-O-$
5 or $-S-$ atoms or $-N(R^{21})-$, $-C(O)-$ or $-C(S)-$ groups], $-CONHet^1$, $-CSNHet^1$, $-$
 $N(R^{21})SO_2NHet^1$, $-N(R^{21})CONHet^1$, $-N(R^{21})CSNHet^1$, $-SO_2N(R^{21})Het^2$ [where
 Het^2 is an optionally substituted monocyclic C_{5-7} carbocyclic group optionally
containing one or more $-O-$ or $-S-$ atoms or $-N(R^{21})-$, $-C(O)-$ or $-C(S)-$ groups],
 $-Het^2$, $-CON(R^{21})Het^2$, $-CSN(R^{21})Het^2$, $-N(R^{21})CON(R^{21})Het^2$, $-$
10 $N(R^{21})CSN(R^{21})Het^2$, aryl or heteroaryl group; Alk^4 is a straight or branched
 C_{1-6} alkylene, C_{2-6} alkenylene or C_{2-6} alkynylene chain, optionally interrupted by
one, two or three $-O-$ or $-S-$ atoms or $-S(O)_g$ [where g is an integer 1 or 2] or
 $-N(R^{21})-$ groups; and f is zero or an integer 1, 2 or 3. It will be appreciated
that when two R^{20} or R^{21} groups are present in one of the above substituents,
15 the R^{20} or R^{21} groups may be the same or different.

When in the group $-Alk^4(R^{19a})_f$ f is an integer 1, 2 or 3, it is to be understood
that the substituent or substituents R^{19a} may be present on any suitable
carbon atom in $-Alk^4$. Where more than one R^{19a} substituent is present these
20 may be the same or different and may be present on the same or different
atom in $-Alk^4$. Clearly, when f is zero and no substituent R^{19a} is present the
alkylene, alkenylene or alkynylene chain represented by Alk^4 then Alk^4
becomes an alkyl, alkenyl or alkynyl group.

25 When R^{19a} is a substituted amino group it may be for example a group $-$
 NHR^{20} [where R^{20} is as defined above] or a group $-N(R^{20})_2$ wherein each R^{20}
group is the same or different.

When R^{19a} is a substituted hydroxyl or substituted thiol group it may be for
30 example a group $-OR^{20}$ or a $-SR^{20}$ or $-SC(=NH)NH_2$ group respectively.

Esterified carboxyl groups represented by the group R^{19a} include groups of
formula $-CO_2Alk^5$ wherein Alk^5 is an alkyl group; a C_{6-12} aryl C_{1-8} alkyl group

such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; an aryl group; a C₆₋₁₂aryloxyC₁₋₈alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an
 5 optionally substituted C₁₋₈alkanoyloxyC₁₋₈alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C₆₋₁₂aryloxyC₁₋₈alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk⁵ group include R^{19a} substituents described above.

10

When Alk⁴ is present in or as a substituent it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally
 15 interrupted by one, two, or three -O- or -S-, atoms or -S(O)-, -S(O)₂- or -N(R²¹)- groups.

When -NHet¹ or -Het² forms part of a substituent R¹⁹ each may be for example an optionally substituted 2- or 3-pyrrolinyl, pyrrolidinyl, pyrazolinyl,
 20 pyrazolidinyl, piperazinyl, imidazolinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, oxazolidinyl or thiazolidinyl group. Additionally Het² may represent for example, an optionally substituted cyclopentyl or cyclohexyl group. Optional substituents which may be present on -NHet¹ or -Het² include those substituents described above in relation to aromatic
 25 groups.

Particularly useful atoms or groups represented by R¹⁹ include fluorine, chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl or t-butyl, optionally substituted phenyl, pyridyl, pyrimidinyl,
 30 pyrrolyl, furyl, thiazolyl, thienyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidinyl or piperidinyl, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC₁₋₆alkyl, e.g. carboxyethyl, C₁₋₆alkylthio e.g. methylthio or ethylthio, carboxyC₁₋₆alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio

or 3-carboxypropylthio, C₁₋₆alkoxy, e.g. methoxy or ethoxy, hydroxyC₁₋₆alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy, pyridyloxy, thiazolyoxy, phenylthio or pyridylthio, C₅₋₇cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, aminoC₁₋₆alkylamino e.g. aminoethylamino, Het¹NC₁₋₆alkylamino e.g. morpholinopropylamino, C₁₋₆alkylaminoC₁₋₆alkyl, e.g. ethylaminoethyl, C₁₋₆dialkylaminoC₁₋₆alkyl, e.g. diethylaminoethyl, aminoC₁₋₆alkoxy, e.g. aminoethoxy, C₁₋₆alkylaminoC₁₋₆alkoxy, e.g. methylaminoethoxy, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, diisopropylaminoethoxy, or dimethylaminopropoxy, hydroxyC₁₋₆alkylamino e.g. hydroxyethylamino, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, nitro, cyano, amidino, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk⁵ [where Alk⁵ is as defined above], C₁₋₆alkanoyl e.g. acetyl, optionally substituted benzoyl, thiol (-SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, -SC(=NH)NH₂, sulphonyl (-SO₃H), -SO₃R²⁰, C₁₋₆alkylsulphinyl e.g. methylsulphinyl, C₁₋₆alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, optionally substituted phenylaminosulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl, e.g. aminoethylaminocarbonyl, C₁₋₆dialkylaminoC₁₋₆alkylaminocarbonyl, e.g. diethylaminoethylaminocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, C₁₋₆alkylaminocarbonylC₁₋₆alkylamino, e.g. methylaminocarbonylmethylamino, aminothiocabonylamino, C₁₋₆alkylaminothiocabonylamino, e.g. methylaminothiocabonylamino or ethylaminothiocabonylamino, C₁₋₆dialkylaminothiocabonylamino, e.g. dimethylaminothiocabonylamino or

diethylaminothiocarbonylamino, C₁₋₆alkylaminothiocarbonylC₁₋₆alkylamino, e.g. ethylaminothiocarbonylmethylamino, -CONHC(=NH)NH₂, C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, optionally substituted phenylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, optionally substituted morpholinesulphonylamino or morpholinesulphonylC₁₋₆alkylamino, optionally substituted phenylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, aminoC₁₋₆alkanoylamino e.g. aminoacetylamino, C₁₋₆dialkylaminoC₁₋₆alkanoylamino, e.g. dimethylaminoacetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, C₁₋₆alkanoylaminoC₁₋₆alkylamino, e.g. acetamidoethylamino, C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino or optionally substituted benzyloxy, benzylamino, pyridylmethoxy, thiazolylmethoxy, benzyloxycarbonylamino, benzyloxycarbonylaminoC₁₋₆alkyl e.g. benzyloxycarbonylaminoethyl, thiobenzyl, pyridylmethylthio or thiazolylmethylthio groups.

Where desired, two R¹⁹ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₁₋₆alkylenedioxy group such as methylenedioxy or ethylenedioxy, or two R¹⁹ substituents may form a cycloimidyl group, for example to form an imidyl group in for example phthalimidyl, or naphthalimidyl such as 1,8-naphthalimidyl.

25

It will be appreciated that where two or more R¹⁹ substituents are present, these need not necessarily be the same atoms and/or groups. In general, the substituent(s) may be present at any available ring position in the aromatic or heteroaromatic group.

30

Examples of C₁₋₃alkyl groups represented by the group Alk¹ in the group R¹ include -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂- and -CH₂CH(CH₃)- groups. Optional substituents which may be present on any carbon atom of

the group Alk^1 include one, two, three or more optional substituents selected from optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic groups as herein defined. When two or more optional substituents are present on carbon atoms of the group Alk^1 these may be joined together with the carbon atoms of Alk^1 to which they are attached to form a cyclic structure. Particular examples include joining two aliphatic or heteroaliphatic chains to form, together with the carbons to which they are attached, a cycloaliphatic or heterocycloaliphatic ring.

10

Aliphatic and cycloaliphatic groups represented by Alk^2 in the group R^1 include those aliphatic and cycloaliphatic groups as herein defined. Optional substituents that may be present on Alk^2 aliphatic and cycloaliphatic groups include halogen atoms. Thus for example, Alk^2 may be a straight or branched C_{1-10} alkyl, C_{2-10} alkenyl or C_{2-10} alkynyl group as defined herein, optionally substituted by one, two, three or more halogen atoms.

In compounds of the invention D may for example be an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl, indenyl, or heteroaromatic group as defined herein for compounds of formula (1).


It will be understood that such Alk^2 aliphatic and cycloaliphatic groups are divalent groups that may be joined to Cy and L^2 in the group R^1 via any available carbon atom or atoms.

Examples of substituents represented by R^1 when present in compounds of the invention include groups $-\text{Alk}^1\text{L}^1\text{CyAlk}^2\text{L}^2\text{D}$ and $-\text{Alk}^1\text{L}^1\text{CyAlk}^2\text{D}$. Particular examples of such substituents include $-\text{CH}_2\text{L}^1\text{CyCH}_2\text{L}^2\text{D}$, $-\text{CH}_2\text{L}^1\text{CyCH}_2\text{D}$, $-\text{CH}_2\text{CH}_2\text{L}^1\text{CyCH}_2\text{L}^2\text{D}$, $-\text{CH}_2\text{CH}_2\text{L}^1\text{CyCH}_2\text{D}$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{L}^1\text{CyCH}_2\text{L}^2\text{D}$, $-\text{CH}_2\text{L}^1\text{CyCH}_2\text{CH}_2\text{L}^2\text{D}$, $-\text{CH}_2\text{L}^1\text{CyCH}_2\text{CH}_2\text{D}$, or $-\text{CH}_2\text{L}^1\text{CyCH}(\text{CH}_3)\text{CH}_2\text{L}^2\text{D}$. More particular examples of such substituents include $-\text{CH}_2\text{CON}(\text{R}^5)\text{CyCH}_2\text{L}^2\text{D}$, $-\text{CH}_2\text{N}(\text{R}^5)\text{COCyCH}_2\text{L}^2\text{D}$, -


30

$\text{CH}_2\text{SO}_2\text{N}(\text{R}^5)\text{CyCH}_2\text{L}^2\text{D}$ and $-\text{CH}_2\text{N}(\text{R}^5)\text{SO}_2\text{CyCH}_2\text{L}^2\text{D}$. In compounds of these types L^2 may be for example, an -O- atom or $-\text{S}(\text{O})_n-$ atom or group in which n is zero or the integer 1 or 2 or $-\text{N}(\text{R}^7)-$ group.

- 5 Optional substituents which may be present on any available carbon of the ring Cy include one, two or three substituents, R^{6A} , where R^{6A} is a halogen atom or an alkyl group. Thus for example Cy may be substituted by a halogen atom or a straight or branched C_{1-10} alkyl group as defined herein.
- 10 Examples of heterocycloaliphatic rings represented by Cy in compounds of the invention include:



where s is the integer 1, t is zero or the integer 2 and a , b , X^- and R^6 are as described earlier, or



- where s is the integer 1 or 2, t is zero or the integer 1 or 2 and a , b , X^- and R^6 are as described earlier.
- 15

Linker atoms or groups L^3 and L^4 , when present in the group R in compounds of the invention may be any of the linker atoms or groups as previously defined for L^5 . Each linker atom or group may be the same or different.

20

- When the groups R^9 and R^{10} or R^{10} and R^{11} are both present in the group R as alkyl groups these groups may be joined together with the N atom to which they are attached to form a heterocyclic ring. Such heterocyclic rings may be optionally interrupted by a further heteroatom selected from -O-, -S- or $-\text{N}(\text{R}^9)-$. Particular examples of such heterocyclic rings include piperidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.
- 25

Example of the substituents represented by R when present in compounds of the invention include atoms or groups $-L^3Alk^3L^4R^8$, $-L^3Alk^3R^8$, $-L^3R^8$, $-R^8$, $-Alk^3R^8$ and $-Alk^3(R^8)_u$ wherein L^3 , Alk^3 , L^4 , R^8 and u are as defined above. Particular examples of such substituents include $-L^3CH_2L^4R^8$, $-L^3CH(CH_3)L^4R^8$, $-L^3(CH_2)_2L^4R^8$, $-L^3CH_2R^8$, $-L^3CH(CH_3)R^8$, $-L^3(CH_2)_2R^8$, $-CH_2R^8$, $-CH(CH_3)R^8$, $-(CH_2)_2R^8$ and $-R^8$ groups.

Particularly useful atoms or groups represented by R in compounds of the invention include for example by one, two, three or more halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, and/or C_{1-6} alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl or t-butyl, optionally substituted C_{3-8} cycloalkyl, e.g. optionally substituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted C_{3-7} heterocycloalkyl, e.g. optionally substituted pyrrolidinyl, piperidinyl, imidazolidinyl, morpholinyl, or piperazinyl, C_{1-6} hydroxyalkyl, e.g. hydroxymethyl, hydroxyethyl or $-C(OH)(CF_3)_2$, carboxy C_{1-6} alkyl, e.g. carboxyethyl, C_{1-6} alkylthio e.g. methylthio or ethylthio, carboxy C_{1-6} alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxypropylthio, C_{1-6} alkoxy, e.g. methoxy or ethoxy, hydroxy C_{1-6} alkoxy, e.g. 2-hydroxyethoxy, halo C_{1-6} alkyl, e.g. $-CF_3$, $-CHF_2$, $-CH_2F$, halo C_{1-6} alkoxy, e.g. $-OCF_3$, $-OCHF_2$, $-OCH_2F$, C_{1-6} alkylamino, e.g. methylamino or ethylamino, amino ($-NH_2$), amino C_{1-6} alkyl, e.g. aminomethyl or aminoethyl, C_{1-6} dialkylamino, e.g. dimethylamino or diethylamino, C_{1-6} alkylamino C_{1-6} alkyl, e.g. ethylaminoethyl, C_{1-6} dialkylamino C_{1-6} alkyl, e.g. diethylaminoethyl, amino C_{1-6} alkoxy, e.g. aminoethoxy, C_{1-6} alkylamino C_{1-6} alkoxy, e.g. methylaminoethoxy, C_{1-6} dialkylamino C_{1-6} alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, diisopropylaminoethoxy, or dimethylamino-propoxy, nitro, cyano, amidino, hydroxyl ($-OH$), formyl [$HC(O)-$], carboxyl ($-CO_2H$), $-CO_2Alk^5$ [where Alk^5 is as previously defined], C_{1-6} alkanoyl e.g. acetyl, thiol ($-SH$), thio C_{1-6} alkyl, e.g. thiomethyl or thioethyl, sulphonyl ($-SO_3H$), $-SO_3Alk^5$, C_{1-6} alkylsulphanyl, C_{1-6} alkylsulphonyl, e.g. methylsulphonyl, amino-sulphonyl ($-SO_2NH_2$), C_{1-6} alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C_{1-6} dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylamino-sulphonyl, phenylaminosulphonyl, carboxamido ($-CONH_2$), C_{1-6} alkyl-aminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C_{1-6} dialkylaminocarbonyl, e.g.

dimethylaminocarbonyl or diethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl, e.g. aminoethylaminocarbonyl, C₁₋₆dialkylamino-C₁₋₆alkylaminocarbonyl, e.g. diethylaminoethylaminocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethyl-aminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, C₁₋₆alkylaminocarbonylC₁₋₆alkyl-amino, e.g. methylaminocarbonylmethylamino, aminothiocabonylamino, C₁₋₆alkylaminothiocabonylamino, e.g. methylaminothiocabonylamino or ethylaminothiocabonylamino, C₁₋₆dialkylaminothiocabonylamino, e.g. dimethylaminothiocabonylamino or diethylaminothiocabonylamino, C₁₋₆alkylaminothiocabonylC₁₋₆alkylamino, e.g. ethylaminothiocabonylmethylamino, C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, aminosulphonylamino (-NH₂SO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, aminoC₁₋₆alkanoylamino e.g. aminoacetylamino, C₁₋₆dialkylamino-C₁₋₆alkanoylamino, e.g. dimethylaminoacetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, C₁₋₆alkanoylaminoC₁₋₆alkylamino, e.g. acetamidoethylamino, C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino groups, optionally substituted C₆₋₁₂aryl e.g. optionally substituted phenyl, optionally substituted C₁₋₉heteroaryl, e.g. optionally substituted pyridyl, pyrimidinyl, thiophenyl or furyl, optionally substituted C₁₋₆alkylC₆₋₁₂aryl, e.g. optionally substituted benzyl or phenylethyl, optionally substituted C₁₋₆alkylC₁₋₉heteroaryl, e.g. optionally substituted pyridylmethyl, furanylmethyl or thiophenylmethyl, C₁₋₆alkoxyC₆₋₁₂aryl, e.g. optionally substituted benzyloxy or phenylethoxy, optionally substituted C₁₋₆alkoxyC₁₋₉heteroaryl, e.g. optionally substituted pyridylmethoxy, furanylmethoxy or thiophenylmethoxy groups.

30

Where desired two R substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₁₋₆alkylenedioxy group such as methylenedioxy or ethylenedioxy. In addition when two R substituents are on adjacent carbon atoms of the heteroaromatic ring of formula (1) they may be

joined to form, together with the heteroaromatic ring carbon atoms to which they are joined, a heteroaromatic ring fused optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic ring where such rings and optional substituents are as previously defined.

5

It will be appreciated that where two or more R substituents are present these need not necessarily be the same atoms and/or groups. In general the substituent(s) may be present on any available ring position in the heteroaromatic ring in compounds of formula (1).

10

R⁶ when present in compounds of formula (1) as an optionally substituted alkyl group may be any optionally substituted alkyl group as previously defined. Particular examples of such groups include C₁₋₆alkyl groups and optionally substituted C₆₋₁₂arylC₁₋₆alkyl groups, especially methyl, ethyl and optionally substituted benzyl groups.

15

A pharmaceutically acceptable counterion means an ion having a charge opposite to that of the substance with which it is associated and that is pharmaceutically acceptable. Representative examples include, but are not limited to, chloride, bromide, iodide, methanesulfonate, p-tolylsulfonate, trifluoroacetate, acetate and the like as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985.

20

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

30


Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isothionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates,

trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.


Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

X in compounds of the invention is preferably an O or S atom or a NR^2 group. Especially useful NR^2 groups include NH , NCH_3 and NCH_2Ph where Ph is an optionally substituted phenyl ring. A most especially preferred X group is an O atom. Thus one group of compounds of the invention has the formula (1a):



wherein R^1 , R, Y and q are as defined for formula (1).

A particularly useful group of compounds according to the invention has the formula (2):



where the numbers 1 to 7 indicate the atom numbering of the heteroaromatic ring according to IUPAC nomenclature and R, q, R¹, R^{1a} and X are as defined for formula (1) or (1a).

and the salts, solvates, hydrates, N-oxides thereof.

5

In general in compounds of formula (1), (1a) and (2) q is preferably zero or the integer 1 or 2.

Each R atom or group when present in compound of formula (2) may be
 10 independently selected from an atom or group $-L^3(Alk^3)_wL^4(R^8)_u$ in which L³, Alk³, w, L⁴, R⁸ and u are as previously defined. Particularly useful R substituents when present in compounds of formula (2) include halogen atoms, especially fluorine, chlorine or bromine atoms, or methyl, halomethyl, especially $-CF_3$ and $-CHF_2$, methoxy or halomethoxy, especially $-OCF_3$ or $-OCHF_2$,
 15 methylenedioxy, ethylenedioxy, $-CN$, $-CO_2R^9$, especially $-CO_2CH_3$; $-COR^9$, especially $-COCH_3$, $-NO_2$, amino ($-NH_2$), substituted amino ($-NR^9R^{10}$) and $-N(R^9)COR^{10}$, especially $-NHCOCH_3$ groups.

In one preferred class of compounds of formula (1) and (2) R^{1a} is a group $-Alk^1L^1CyAlk^2L^2D$.
 20

In another preferred class of compounds of formula (1) and (2) R¹ is a group $-Alk^1L^1CyAlk^2L^2D$ and R^{1a} is an atom or group R. In one preferred group of compounds in this class R^{1a} is a hydrogen atom.

25

In another preferred class of compounds of formula (1), (1a) and (2) R¹ is a group $-Alk^1L^1CyAlk^2L^2D$ where R¹ is attached to the carbon atom numbered 4.

30 In another preferred class of compounds of formula (1), (1a) and (2) R¹ is a group $-Alk^1L^1CyAlk^2L^2D$ where R¹ is attached to the carbon atom numbered 5.

In another preferred class of compounds of formula (1), (1a) and (2) q is the integer 1 and R is attached to the carbon atom numbered 2. In one preferred group of compounds of this class R is a halogen atom, especially a fluorine, chlorine or bromine atom. In another preferred group of compounds of this class R is the group $-\text{SR}^9$ or $-\text{OR}^9$. In this group of compounds R^9 is preferably a $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$ or $-\text{CH}(\text{CH}_3)_2$ group. Most especially preferred R atoms or groups in this class of compounds include chlorine atoms and $-\text{SCH}_3$ groups.

10 In general in compounds of formula (1), (1a) and (2) Alk^1 in the substituent $-\text{Alk}^1\text{L}^1\text{CyAlk}^2\text{L}^2\text{D}$ is preferably an optionally substituted $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$ group. When Alk^1 is substituted it is preferably substituted with an optionally substituted aliphatic group, in particular $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}(\text{CH}_3)_2$, $-(\text{CH}_2)_2\text{CH}_3$, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$, or $-\text{C}(\text{CH}_3)_3$, especially $-\text{CH}(\text{CH}_3)_2$ or $-\text{C}(\text{CH}_3)_3$.

In general in compounds of formula (1), (1a) and (2) L^1 in the substituent $-\text{Alk}^1\text{L}^1\text{CyAlk}^2\text{L}^2\text{D}$ is preferably a $-\text{CON}(\text{R}^5)-$ group. R^5 in this L^1 group is preferably a hydrogen atom or a C_{1-6} alkyl group, especially a $-\text{CH}_3$ or $-\text{CH}_2\text{CH}_3$ group.

In one preferred class of compounds of formula (1), (1a) and (2) R^1 is the group $-\text{Alk}^1\text{L}^1\text{CyAlk}^2\text{L}^2\text{D}$ in which L^1 is preferably the group $-\text{CON}(\text{R}^5)-$ in which R^5 is preferably a hydrogen atom or $-\text{CH}_3$ or $-\text{CH}_2\text{CH}_3$ group, L^2 is preferably a covalent bond and Alk^2 is preferably an optionally substituted C_{1-6} aliphatic group. Especially useful Alk^2 groups include optionally substituted $-\text{CH}_2-$, $-\text{CH}(\text{CH}_3)-$ and $-\text{CH}_2\text{CH}_2-$ groups.

In another preferred class of compounds of formula (1), (1a) and (2) R^1 is the group $-\text{Alk}^1\text{L}^1\text{CyAlk}^2\text{L}^2\text{D}$ in which L^1 is preferably the group $-\text{CON}(\text{R}^5)-$ in which R^5 is preferably a hydrogen atom or $-\text{CH}_3$ or $-\text{CH}_2\text{CH}_3$ group, L^2 is preferably an $-\text{O}-$ or $-\text{S}-$ atom or $-\text{N}(\text{R}^7)-$ group in which R^7 is preferably a hydrogen atom or $-\text{CH}_3$ or $-\text{CH}_2\text{CH}_3$ group and Alk^2 is preferably an

optionally substituted C₁₋₆aliphatic group. A most especially useful L² atom is an -O- atom. Especially useful Alk² groups in this class of compounds include optionally substituted -CH₂-, -CH(CH₃)- and -CH₂CH₂- groups.

- 5 In another preferred class of compounds of formula (1), (1a) and (2) s and t in the heterocycloaliphatic ring Cy are each the integer 1.

In another preferred class of compounds of formula (1), (1a) and (2) D is an optionally substituted cycloaliphatic group, particularly an optionally substituted C₃₋₈cycloalkyl or C₃₋₈cycloalkenyl group. Particularly preferred
10 optionally substituted C₃₋₈cycloalkyl groups include cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups. Particularly preferred optionally substituted C₃₋₈cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl groups.

15

Compounds according to the invention are potent and selective inhibitors of chemokine binding to the CCR-3 receptor. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.

20

The compounds are of use in modulating chemokine mediated cell signalling and in particular are of use in the prophylaxis and treatment of diseases or disorders involving inappropriate migration of cells. The invention extends to such a use and to the use of the compounds of formula (1) for the
25 manufacture of a medicament for treating such diseases and disorders. Particular diseases include inflammatory diseases and immune disorders.

Particular uses to which the compounds of the invention may be put include the treatment or inhibition of asthma, especially bronchial asthma, eczema,
30 conjunctivitis, allergic rhinitis, nasal polyposis, atopic dermatitis, pruritis, psoriasis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis,

thrombosis, Alzheimer's disease, graft vs host rejection, allograft rejection, HIV infection, rheumatoid arthritis, Acquired Immune Deficiency Syndrome and atherosclerosis.

- 5 For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

10

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, vaginal or rectal administration, or a form suitable for administration by inhalation or insufflation.

15

- For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

25

30

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

- 5 The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous
10 vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. For particle mediated administration the compounds of formula (1) may be coated on particles such as microscopic gold
15 particles.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular
20 injection.

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with
25 the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

For vaginal or rectal administration the compounds of formula (1) may be
30 formulated as a suppository. These formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is a solid at room temperature but liquid at the body temperature. Such materials include for example cocoa butter and polyethylene glycols.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

5


The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around
10 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

15 The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. Many of the reactions described are well-known standard synthetic methods which may be applied to a variety of compounds and as such can be used not only to generate compounds of the invention, but also
20 where necessary the intermediates thereto.

In the following process description, the symbols Alk^1 , h, R^3 , R, q, Y, X, Cy, R^{17} , L^2 , Alk^2 , n, D, R^{1a} , Alk^3 , w, L^4 , R^8 , u, Alk^5 , R^9 and R^{20} when used in the formulae depicted are to be understood to represent those groups described
25 above in relation to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard
30 practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, (1999) and the examples herein]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described

hereinafter are to be understood to extend to such removal of protecting groups.

Thus according to a further aspect of the invention, a compound of formula (1) in which L^1 is a $-\text{CON}(\text{R}^5)-$ group may be obtained by coupling of a compound of formula (3):



10

in which W is a $-\text{CO}_2\text{H}$ group with a compound of formula $\text{HN}(\text{R}^5)\text{CyAlk}^2\text{L}^2\text{D}$.

The reaction may be performed in the presence of a base, such as a hydride; e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g. dimethylformamide at for example ambient temperature in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N, N'-dicyclohexylcarbodiimide, advantageously in the presence of a catalyst such as a N-hydroxy compound e.g. a N-hydroxytriazole such as 1-hydroxytriazole. Alternatively the acid in compounds of formula (3) may be activated by for example conversion to an acid halide such as an acid chloride by reaction with a halogenating agent such as thionyl chloride or oxalyl chloride in a solvent such as a halogenated hydrocarbon e.g. dichloromethane or converted to a chloroformate, for example ethyl chloroformate, prior to the desired coupling reaction under the conditions just described.


A compound of formula (1) in which L^1 is a $-\text{SO}_2\text{N}(\text{R}^5)-$ group may be obtained by coupling of a compound of formula (3) in which W is a $-\text{SO}_2\text{Cl}$

30

group with a compound of formula $\text{HN}(\text{R}^5)\text{CyAlk}^2\text{L}^2\text{D}$ under the reaction conditions just described for the coupling of acid halides of formula (3).

It will be appreciated that similar reagents and conditions can be used to obtain compounds of formula (1) in which L^1 is a $-\text{N}(\text{R}^5)\text{CO}-$ or $-\text{N}(\text{R}^5)\text{SO}_2-$ group using a compound of formula (3) in which W is a $-\text{N}(\text{R}^5)\text{H}$ group and a compound of formula $\text{V-CyAlk}^2\text{L}^2\text{D}$ where V is a $\text{HO}_2\text{C}-$ or $\text{ClO}_2\text{S}-$ group.

Alternatively compounds of formula (1) may be prepared by reaction of a compound of formula (3A):



with an $\text{Alk}^{2a}\text{L}^2\text{D}$ group, wherein Alk^{2a} is a suitable precursor to Alk^2 , for example Alk^{2a} contains a reactive group, such as a carbonyl or a leaving group e.g. a halogen. This reaction may be achieved using methods known to those skilled in the art. In the case where Alk^{2a} incorporates a carbonyl group, such as a ketone or an aldehyde, this may be reacted with (3A) in the presence of a suitable reducing agent to give a compound of formula (1). Appropriate conditions may include the use of a suitable borohydride as reductant, for example sodium triacetoxyborohydride or sodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. methanol or ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature.

Intermediates of formula (3A) may be prepared using standard coupling procedures as described above for the synthesis of compounds of formula (1). For example a compound of formula (3) may be reacted with a $\text{HN}(\text{R}^5)\text{Cy}$ group using conditions described herein. It will be appreciated that for optimal results reactive sites may be suitably protected prior to reaction and then subsequently removed, using standard techniques.


Intermediates of formula (3), (3A) and any other intermediates required to obtain compounds of formula (1) may be prepared by methods known to those skilled in the art following procedures set forth in references such as *Rodd's Chemistry of Carbon Compounds*, Volumes 1-15 and Supplementals
 5 (Elsevier Science Publishers, 1989), *Fieser and Fieser's Reagents for Organic Synthesis*, Volumes 1-19 (John Wiley and Sons, 1999), *Comprehensive Heterocyclic Chemistry*, Ed. Katritzky *et al*, Volumes 1-8, 1984 and Volumes 1-11, 1994 (Pergamon), *Comprehensive Organic Functional Group Transformations*, Ed. Katritzky *et al*, Volumes 1-7, 1995
 10 (Pergamon), *Comprehensive Organic Synthesis*, Ed. Trost and Fleming, Volumes 1-9, (Pergamon, 1991), *Encyclopedia of Reagents for Organic Synthesis* Ed. Paquette, Volumes 1-8 (John Wiley and Sons, 1995), *Larock's Comprehensive Organic Transformations* (VCH Publishers Inc., 1989) and *March's Advanced Organic Chemistry* (John Wiley and Sons, 1992)

15

Thus, for example, intermediates of formula $\text{HN}(\text{R}^5)\text{CyAlk}^2\text{L}^2\text{D}$, may be prepared by reductive alkylation of a compound of formula $\text{HN}(\text{R}^5)\text{Cy}$ with an $\text{Alk}^{2a}\text{L}^2\text{D}$ group, in which Alk^{2a} is as defined herein, using methods known to those skilled in the art. Appropriate conditions may include the use of a
 20 suitable borohydride as reductant, for example sodium triacetoxyborohydride or sodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. methanol or ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature.

25

Intermediates of formula (3) in which X and Y are both heteroatoms may be prepared by reaction of intermediates of formula (4):



30

with for example an acylating agent or derivative thereof such as an acid halide of formula RCOHal [where Hal is a halogen atom such as a chlorine atom], a xanthate salt e.g. a salt of ethyl xanthate such as the potassium salt $(\text{CH}_3\text{CH}_2\text{OC}(=\text{S})\text{SK})$, an amidine $(\text{RC}(=\text{NH})\text{NH}_2)$ or a urea
5 $(\text{H}_2\text{NC}(=\text{NH})\text{NHR})$.

The reaction may be performed optionally in the presence of a base such as a hydride, e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, optionally in a solvent such as a halogenated
10 hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g. dimethylformamide or an alcohol such as methanol or ethanol at a temperature from ambient temperature to the reflux temperature.

Intermediates of formula (3) in which Y is the group CR^{1a} and X is the group
15 NH may be prepared from optionally substituted anilines of formula PhNH_2 and α -halomethylketones of formula $\text{HalCH}_2\text{COR}^{1a}$ by initial alkylation of the aniline followed by acid catalysed cyclization to give an intermediate of formula (3).

20 The alkylation may be carried out in the presence of a base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium *t*-butoxide, a hydride, e.g. sodium hydride or an organic amine, e.g. triethylamine or N,N-diisopropylethylamine or a cyclic amine, e.g. N-methylmorpholine or pyridine, in a dipolar aprotic solvent such as an amide,
25 e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran.

Acid catalyzed cyclization may be performed using an acid such as polyphosphoric acid or a Lewis acid such as aluminium chloride optionally in
30 the presence of a solvent such as a halogenated hydrocarbon, e.g. dichloromethane.

Intermediates of formula (3) in which Y is the group CR^{1a} and X is an O atom may be prepared from an optionally substituted phenol of formula PhOH and

a halide of formula $R^{29}O_2CCH(Hal)COR^{1a}$ [where R^{29} is an alkyl group] by initial alkylation of the phenol followed by acid catalysed cyclization, under the conditions just described, to give an intermediate of formula (3).

- 5 Intermediates of formulae (3), $HN(R^5)CyAlk^2L^2D$, $HN(R^5)Cy$ and $OHCAIk^2L^2D$ may be further derivatised by one or more standard synthetic methods employing substitution, oxidation, reduction or cleavage reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, thioacylation, halogenation, sulphonylation, nitration, formylation and coupling procedures. It will be appreciated that these methods may also be used to obtain or modify other compounds of formulae (1) and (2) where appropriate functional groups exist in these compounds.

- 15 Intermediates of formula (3) in which R is a group NHR^a where R^a is an aromatic or heteroaromatic group may be prepared by reaction of an intermediate of formula (3) where R is an NH_2 group with a compound of formula Z^3R^a [where Z^3 is a halogen atom such as a bromine or iodine atom or a trifluoromethanesulfonate group]. The reaction may be carried out in the presence of a metal complex catalyst such as a palladium complex, e.g. dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II), optionally in the presence of an organic base, for example an alkoxide such as sodium t-butoxide, in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran, at an elevated temperature e.g. the reflux temperature.

- 25 Intermediates of formula (3) in which R is a group $-(Alk^3)_wL^4(R^8)_u$ may be prepared by reaction of an intermediate of formula (3) in which R is a halogen atom such as a bromine or iodine atom with an organometallic reagent $HalM(Alk^3)_wL^4(R^8)_u$, where M is a metal atom such as a zinc or magnesium atom and Hal is a halogen atom such as a bromine atom. The reaction may be carried out in the presence of a metal catalyst such as a palladium complex, e.g. tetrakis(triphenylphosphine)palladium (0), in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at an elevated temperature, e.g. the reflux temperature.

Compounds of the invention and intermediates thereto may be prepared by alkylation, arylation or heteroarylation. For example, compounds containing a $-L^2H$ or $-L^3H$ group (where L^2 and L^3 is each a linker atom or group) may be treated with an alkylating agent DZ^1 or $(R^8)_uL^4(Alk^3)_wZ^1$ respectively in which Z^1 is a leaving atom or group such as a halogen atom, e.g. a fluorine, bromine, iodine or chlorine atom or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy, e.g. p-toluenesulphonyloxy group.

10 The reaction may be carried out in the presence of a base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran.

15

In another example, compounds containing a $-L^3H$ group as defined above may be functionalised by acylation or thioacylation, for example by reaction with one of the alkylating agents just described but in which Z^1 is replaced by a $-C(O)Z^2$, $C(S)Z^2$, $-N(R^{17})COZ^2$ or $-N(R^{17})C(S)Z^2$ group in which Z^2 is a leaving atom or group as described for Z^1 . The reaction may be performed in the presence of a base, such as a hydride, e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g. dimethylformamide, at for example ambient temperature. Alternatively, the acylation may be carried out under the same conditions with an acid (for example one of the alkylating agents described above in which Z^1 is replaced by a $-CO_2H$ group) in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N,N'-dicyclohexylcarbodiimide, or a benzotriazole such as [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophosphate advantageously in the presence of a catalyst such as a N-hydroxy compound e.g. a N-hydroxybenzotriazole such as 1-hydroxybenzotriazole. Alternatively the acid may be reacted with a chloroformate, for example ethylchloroformate, prior to the desired acylation reaction

In a further example compounds may be obtained by sulphonylation of a compound containing an -OH group by reaction with one of the above alkylating agents but in which Z^1 is replaced by a -S(O)Hal or -SO₂Hal group [in
5 which Hal is a halogen atom such as chlorine atom] in the presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature.

10 In another example, compounds containing a -L²H or -L³H group as defined above may be coupled with one of the alkylation agents just described but in which Z^1 is replaced by an -OH group in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl, diisopropyl- or dimethylazodicarboxylate.

15 In a further example, ester groups -CO₂R¹² or -CO₂Alk⁵ in the compounds may be converted to the corresponding acid [-CO₂H] by acid- or base-catalysed hydrolysis depending on the nature of the groups R¹² or Alk⁵. Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic
20 or inorganic acid, e.g. trifluoroacetic acid in an aqueous solvent or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol. Similarly an acid [-CO₂H] may be prepared by hydrolysis of the corresponding nitrile [-CN], using for example a base such as sodium hydroxide
25 in a refluxing alcoholic solvent, such as ethanol.

In a further example, -OR⁹ or -OR²⁰ groups [where R⁹ or R²⁰ each represents an alkyl group such as methyl group] in compounds of formula (1) may be cleaved to the corresponding alcohol -OH by reaction with boron tribromide in
30 a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C.

Alcohol [-OH] groups may also be obtained by hydrogenation of a corresponding -OCH₂R³⁰ group (where R³⁰ is an aryl group) using a metal

catalyst, for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature. In another example, -OH groups may be generated from the corresponding ester [e.g. CO_2Alk^5 or CO_2R^{12}] or aldehyde [-CHO] by reduction, using for example a complex metal
5 hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol. Alternatively an alcohol may be prepared by reduction of the corresponding acid [- CO_2H], using for example lithium aluminium hydride in a solvent such as tetrahydrofuran.

10

In another example, alcohol -OH groups in the compounds may be converted to a corresponding - OR^9 or - OR^{20} group by coupling with a reagent R^9OH or R^{20}OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or
15 dimethylazodicarboxylate.

Aldehyde [-CHO] groups may be obtained by oxidation of a corresponding alcohol using well known conditions. For example using an oxidising agent such as a periodinane e.g. Dess Martin, in a solvent such as a halogenated
20 hydrocarbon, e.g. dichloromethane. An alternative oxidation may be suitably activating dimethyl sulfoxide using for example, oxalyl chloride, followed by addition of an alcohol, and subsequent quenching of the reaction by the addition of an amine base, such as triethylamine. Suitable conditions for this reaction may be using an appropriate solvent, for example, a halogenated
25 hydrocarbon, e.g. dichloromethane at -78°C followed by subsequent warming to room temperature.

α,β -Unsaturated aldehydes, for example, of formula OHCD , where D is alkenyl or cycloalkenyl, may be prepared by hydrolysis of a corresponding allylic nitro
30 compound. This may be achieved, for example, by treatment of the allylic nitro compound with a base, such as sodium methoxide or potassium *tert*-butoxide, followed by addition of a buffered aqueous titanium trichloride solution. The allylic nitro compound may be prepared by nucleophilic addition of nitromethane to the corresponding ketone, followed by elimination of water.

Suitable conditions for this reaction may be refluxing in toluene under Dean Stark conditions, in the presence of an amine base, such as N,N-dimethylethylene diamine. It will be appreciated that these aldehydes may be used in reductive alkylations to give compounds of formula (1), where Alk^2 is –
5 CH_2 – and L^2 is a covalent bond, using the conditions described herein.

Aminosulphonylamino [$-\text{NHSO}_2\text{NHR}^{20}$] groups in the compounds may be obtained, in another example, by reaction of a corresponding amine [$-\text{NH}_2$] with a sulphamide $\text{R}^{20}\text{NHSO}_2\text{NH}_2$ in the presence of an organic base such as
10 pyridine at an elevated temperature, e.g. the reflux temperature.

In another example compounds containing a $-\text{NHCSR}^{20}$ or $-\text{CSNHR}^{10}$, may be prepared by treating a corresponding compound containing a $-\text{NHCOR}^{20}$ or $-\text{CONHR}^{10}$ group with a thiation reagent, such as Lawesson's Reagent or P_2S_5 ,
15 in an anhydrous solvent, for example a cyclic ether such as tetrahydrofuran, at an elevated temperature such as the reflux temperature.

In a further example amine ($-\text{NH}_2$) groups may be alkylated using a reductive alkylation process employing an aldehyde and a borohydride, for example
20 sodium triacetoxyborohydride or sodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature. Amines of formula $-\text{NH}(\text{CH}_3)$ may be prepared by reacting the corresponding amine [$-\text{NH}_2$] with aqueous
25 formaldehyde and cyclopentadiene in a suitable solvent such as water followed by reaction with trifluoroacetic acid and triethylsilane in a suitable halogenated hydrocarbon, e.g. dichloromethane to give the desired amine.

In a further example, amine [$-\text{NH}_2$] groups in compounds of formula (1) may be
30 obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

In another example, a nitro [$-\text{NO}_2$] group may be reduced to an amine [$-\text{NH}_2$], for example by catalytic hydrogenation using for example hydrogen in the

presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol e.g. methanol, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

5

In a further example amine ($-\text{CH}_2\text{NH}_2$) groups in compounds of formula (1) and intermediates thereto may be obtained by reduction of nitriles ($-\text{CN}$), for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon, or Raney® nickel, in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran or an alcohol, e.g. methanol or ethanol, optionally in the presence of ammonia solution at a temperature from ambient to the reflux temperature, or by chemical reduction using for example a metal hydride, e.g. lithium aluminium hydride, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a temperature from 0°C to the reflux temperature.

15

Aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange with a base, for example a lithium base such as n-butyl or t-butyl lithium, optionally at a low temperature, e.g. around -78°C , in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent. Thus, for example, a formyl group may be introduced by using dimethylformamide as the electrophile; a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile.

20

In another example, sulphur atoms in the compounds, for example when present in a linker group L^2 or L^3 may be oxidised to the corresponding sulfoxide or sulphone using an oxidising agent such as a peroxy acid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.

25

N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C , or alternatively by

30

reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

Nitrogen quaternised derivatives of compounds of formula (1) may be formed
5 by reaction of a compound of formula (1) with an alkylating agent such as an alkyl halide, e.g. methyl or ethyl iodide or a benzyl halide such as benzyl bromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or an alcohol, e.g. methanol or ethanol or a mixture of such solvents at for example ambient temperature.

10

Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate base or acid in a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol or an aqueous solvent using conventional procedures.
15 Salts of compounds of formula (1) may be exchanged for other salts by use of conventional ion-exchange chromatography procedures.

Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using
20 any suitable conventional procedure for resolving enantiomers.

Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then
25 be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separated
30 using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.

Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.

The following Examples illustrate the invention. All temperatures are in °C.

- 5 Where experimental detail is not given for the preparation of a reagent it is either commercially available, or it is known in the literature, for which the CAS number is quoted. The following abbreviations are used:

- | | |
|--|---|
| NMM - N-methylmorpholine; | EtOAc - ethyl acetate; |
| MeOH - methanol; | BOC - butoxycarbonyl; |
| 10 DCM - dichloromethane; | AcOH - acetic acid; |
| DIPEA - diisopropylethylamine; | EtOH - ethanol; |
| Pyr - pyridine; | DMF - N,N-dimethylformamide; |
| DMSO - dimethylsulphoxide; | iPr - isopropyl; |
| Et ₂ O - diethylether; | Me - methyl; |
| 15 THF - tetrahydrofuran; | RT - room temperature; |
| Et ₃ N - triethylamine; | LiAlH ₄ - lithium aluminium hydride; |
| DMF - N,N-dimethylformamide | |
| EDC.HCl - 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; | |
| DMAP - 4-dimethylaminopyridine | |
| 20 NMRs were obtained at 400MHz unless otherwise indicated. | |

INTERMEDIATE 1

1-Cyclooct-1-enylmethylpiperidin-4-ylamine dihydrochloride

- (Boc-4-amino)piperidine.HCl (4.56 g), triethylamine (2.6 ml), molecular sieves
 25 (1 g) and THF (200 ml) were combined under a nitrogen atmosphere at RT. Cyclooct-1-enecarbaldehyde (CAS No. 6038-12-6) (4 g) was added and the reaction mixture stirred for 15 mins. NaBH(OAc)₃ (8 g) was added and the reaction was stirred at RT for 16h. The reaction mixture was then evaporated *in vacuo* and the resulting residue was taken up in DCM (200 ml), washed with
 30 H₂O (2 x 100 ml), saturated aqueous NaHCO₃ (100 ml), dried (MgSO₄) and evaporated *in vacuo* to give a yellow oil (6.94 g). The yellow oil was dissolved in MeOH (50 ml) and 1N HCl in Et₂O (110 ml) was added. The reaction mixture was stirred at RT for 2h. The resulting precipitate was filtered and washed with Et₂O to give the title compound as a white solid. Evaporation of the filtrate *in*

vacuo and trituration with Et₂O gave a second crop of the title compound as a beige solid. MS 223 (M+H).

INTERMEDIATE 2

5 (2-Methylsulfanylbenzoxazol-5-yl)acetic acid

(3-Amino-4-hydroxyphenyl)acetic acid (4 g), EtOH (50 ml) and potassium ethyl xanthate (4.6 g) were combined and heated to reflux for 5h. The reaction mixture was allowed to cool to RT, iodomethane (3.3 ml) was added and the whole stirred for 16h. The EtOH was removed by evaporation *in vacuo* and the residue was partitioned between EtOAc (250 ml) and H₂O (250 ml). The organic layer was washed with H₂O (250 ml), brine (250 ml), dried (MgSO₄) and evaporated *in vacuo* to give the title compound as a beige solid. MS 224 (M+H).

15 INTERMEDIATE 3

Benzofuran-3-yl-acetic acid ethyl ester

3-Coumaranone (1.50 g) and (carboethoxymethylene)triphenylphosphorane (5.84 g) were refluxed in toluene (50 ml) for 48 hours. The toluene was removed *in vacuo* and the residue was purified by flash chromatography to give the title compound as a near colourless oil (1.75g) R_f = 0.18 (10:1 hexane/EtOAc); MS 205 (M+H)

INTERMEDIATE 4

Benzofuran-3-yl-acetic acid

25 To a stirring solution of Intermediate 3 (1.00 g) in methanol (20 ml) was added a solution of lithium hydroxide (2.05 g) in water. The mixture was stirred for 2 hours before diluting with water (50 ml) and washing with hexane (20 ml). The aqueous layer was acidified (HCl, pH1) and extracted with EtOAc (4 x 50 ml). The combined organic layers were washed with water (2 x 25 ml), brine (25 ml), dried (MgSO₄) and evaporated *in vacuo* to give the title compound as an off-white solid. MS 177 (M+H).

INTERMEDIATE 5

3-Benzofuran-4-yl-propionic acid

To a stirred solution of 3-(1-benzofuran-4-yl)prop-2-enoic acid (CAS 209256-70-2, 382 mg) in ethanol (30 ml) was added palladium on charcoal (10%, 10 mg). The mixture was hydrogenated for 4 hrs before the catalyst was filtered and washed with ethanol. The filtrate was evaporated *in vacuo* and the residue
5 was purified by flash chromatography to give the title compound as a near colourless oil (113 mg) $R_f = 0.28$ (1:1 hexane/EtOAc); MS 191 (M+H).

INTERMEDIATE 6

Benzothiophen-3-yl-acetic acid

10 3-Benzothiopheneacetonitrile (CAS No. 3216-48-6) (5.0 g) and sodium hydroxide (8 g) was heated to reflux in ethanol/water (3:1, 80 ml) for 3 hrs. The mixture was cooled evaporated *in vacuo* and acidified. The solid precipitate was collected, washed with water and dried to give the title compound as a beige solid R_f 0.40 (Ether).

15

INTERMEDIATE 7

4-(2-Benzofuran-4-yl-acetylamino)piperidine-1-carboxylic acid tert-butyl ester

2-(Benzofuran-4-yl)acetic acid (2.22 g), Boc-(4-amino)piperidine.HCl (2.99 g)
20 and DCM (50 ml) were combined under a nitrogen atmosphere at RT. Triethylamine (3.52 ml) was added, followed by DMAP (10 mg) and EDC.HCl (3.62 g) and the reaction mixture stirred for 16h at RT. 1M NaOH (50 ml) was added, organic layer was separated and washed with 1M NaOH (50ml) and brine (50 ml), dried ($MgSO_4$) and evaporated *in vacuo* to give a yellow solid
25 (5.85 g). The crude residue was dissolved in EtOAc and washed through a pad of silica with 15% DCM, EtOAc. The filtrate was collected and evaporated to dryness *in vacuo* to give the title compound as a cream solid (4.11g). $R_f = 0.27$ (50% EtOAc/hexane); δH ($CDCl_3$) 7.20 (1H, d), 7.50 (1H, d), 7.30 (1H, t), 7.10 (1H, d), 6.80 (1H, d), 5.25 (1H, d), 4.10-3.90 (3H, m), 3.85 (2H, s), 2.80 (2H, t),
30 1.80 (2H, dd), 1.45 (9h, s), 1.20-1.00 (2H, m); MS 359 (M+H).

INTERMEDIATE 8

2-Benzofuran-4-yl-N-piperidin-4-yl-acetamide hydrochloride

Intermediate 7 (3.39 g) was dissolved in MeOH (50 ml) under a nitrogen atmosphere, 1M HCl (in Et₂O) (95 ml) was added and reaction stirred at RT for 3h. Reaction mixture was evaporated to dryness *in vacuo* to yield the title compound as a cream foam (2.3 g). MS 259 ((M-HCl)+H).

5

INTERMEDIATE 9

2-Cyclohexyl-propionaldehyde

Oxalyl chloride (0.55 ml) and DMSO (0.90 ml) were added to cooled DCM (15 ml) at -78°C and the reaction stirred for 5 min. 2-Cyclohexyl-1-propanol (0.50 ml) was then added dropwise and the reaction stirred at -78°C for 1.5h. Triethylamine (3.1 ml) was then added and the reaction allowed to reach RT and stirred for a further 1.5h. The reaction mixture was partitioned between DCM (40 ml) and water (40 ml). The aqueous layer was back-extracted with DCM (40 ml) and the combined organics washed with water (2 x 40 ml), dried (MgSO₄) and evaporated to dryness *in vacuo* to yield a yellow oil (721 mg). The product was purified by flash chromatography (5% EtOAc/hexane) to yield the title compound as a yellow oil (272 mg). R_f = 0.39 (5% EtOAc/hexane); δH (CDCl₃) 9.65 (1H, d), 2.35-2.15 (1H, m), 1.90-1.60 (7H, m), 1.45-1.10 (4H, m), 1.05 (3H, d).

20

INTERMEDIATE 10

3-(2-Benzofuran-4-yl-acetylamino)piperidine-1-carboxylic acid tert-butyl ester

2-(Benzofuran-4-yl)acetic acid (0.77 g) and (±)-(3-amino-1-Boc)piperidine. (0.88 g) were dissolved in DCM (15 ml) under a nitrogen atmosphere. Triethylamine (1.23 ml) was added, followed by DMAP (10 mg) and EDC.HCl (1.26 g) and the reaction mixture stirred for 16h at RT. DCM (25 ml) was added, the reaction mixture washed with 1M NaOH (2 x 30 ml) and brine (30 ml), dried (MgSO₄) and evaporated *in vacuo* to give a cream solid. The product was purified by flash chromatography (5% MeOH, DCM) to yield the title compound as a cream solid (0.94 g). R_f = 0.74 (10% MeOH, DCM); δH (CDCl₃) 7.65 (1H, d), 7.45 (1H, d), 7.30-7.25 (1H, m), 7.10 (1H, d), 6.80 (1H, d),

30

5.45 (1H, br s), 4.00-3.85 (1H, m), 3.80 (2H, s), 3.50 (1H, d), 3.35-3.00 (3H, m), 1.75-1.60 (2H, m), 1.40 (9H, s); MS 359.0 (MH⁺), 381.2 (M+Na).

INTERMEDIATE 11

5 2-Benzofuran-4-yl-N-piperidin-3-yl-acetamide hydrochloride

Intermediate 10 (0.94 g) was dissolved in MeOH (50 ml) under a nitrogen atmosphere, 1M HCl (in Et₂O) (95 ml) was added and reaction stirred at RT for 16h. Reaction mixture was evaporated to dryness *in vacuo* to yield the title compound as a pale yellow solid (0.93 g) MS 259.3 ((M-HCl)+H).

10

INTERMEDIATE 12

3-(3,4-Dichlorophenyl)propan-1-ol

3-(3,4-Dichlorophenyl)propionic acid (1.38 g) was dissolved in THF (40 ml) under a nitrogen atmosphere and cooled to 0°C. LiAlH₄ (0.24 g) was added and the reaction stirred for 22h at RT. The reaction was quenched by addition of EtOAc (2 ml), H₂O (1.5 ml) and 1M NaOH (0.5 ml) and the mixture was stirred for a further 30 min. The reaction mixture was then filtered through Celite® and concentrated *in vacuo*. H₂O (10 ml) was added and then extracted with DCM (2 x 10 ml). Combined organics were dried (MgSO₄) and evaporated to dryness *in vacuo*. The product was purified by flash chromatography (5% MeOH, DCM) to yield the title compound as a colourless oil (0.63 g). R_f = 0.50 (10% MeOH, DCM); δH (CDCl₃) 7.40-7.25 (2H, m), 7.00 (1H, dd), 3.65 (2h, t), 2.70 (2H, t), 1.90-1.80 (2H, m).

25 INTERMEDIATE 13

2-Methyl-3-phenylpropan-1-ol

α-Methylhydrocinnamic acid (1.25 g) was dissolved in THF (20 ml) under a nitrogen atmosphere and LiAlH₄ (1M solution in THF) (8.4 ml) was added and reaction stirred for 16h at RT. The reaction was quenched and worked up as described for intermediate 12 to yield the title compound as a colourless oil (1.09 g). The product was purified by flash chromatography (50% EtOAc, hexane) to yield the title compound as a colourless oil (0.55g). R_f = 0.64 (10% MeOH, DCM); δH (CDCl₃) 7.30-7.10 (5H, m), 3.60-3.40 (2h, m), 2.80-2.70 (1H, m), 2.45-2.35 (1H, m), 2.00-1.85 (1H, m), 0.95 (3H, d).

INTERMEDIATE 14**3-(3,4-Dichlorophenyl)propanal**

Intermediate 12 (0.51 g) was dissolved in DCM (15 ml) under an atmosphere of
5 nitrogen. Dess-Martin periodinane (1.2 g) was added and reaction stirred at RT
for 6h. 1M NaOH (15 ml) added and stirred for a further 30 min. The reaction
mixture was separated, and the aqueous back-extracted with DCM (2 x 20 ml).
The combined organics were washed with brine (20 ml) and dried (MgSO₄) and
evaporated to dryness *in vacuo* to yield the title compound as a yellow oil (0.38
10 g). R_f = 0.87 (10% MeOH, DCM); δ H (CDCl₃) 9.80 (1H, s), 7.40-7.25 (2H, m),
7.00 (1H, dd), 2.95-2.85 (2H, m), 2.80-2.75 (2H, m).

Similarly prepared was:

INTERMEDIATE 15**2-Methyl-3-phenylpropanal**

From Intermediate 13 (0.31 g) as a colourless oil. R_f = 0.89 (50%
EtOAc/hexane).

EXAMPLE 1**2-Benzofuran-4-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide**

2-(1-Benzofuran-4-yl)acetic acid (200 mg), EDCI·HCl (326 mg), Intermediate 1
(335 mg), DMAP (10 mg), Et₃N (0.63 ml) and DCM (20 ml) were combined
under a nitrogen atmosphere and stirred at RT for 16h. The reaction mixture
25 was then diluted with DCM (20 ml), washed with 1N aqueous NaOH solution
(20 ml) and evaporated *in vacuo* onto silica. Purification by flash
chromatography gave the title compound as an off white solid. R_f = 0.4 (10%
MeOH, CH₂Cl₂); δ H (d₆-DMSO) 8.1(1H, d), 7.95 (1H, s), 7.45 (1H, m), 7.25 (1H,
m), 7.10 (1H, m), 7.05 (1H, s), 5.45 (1H, t), 3.65 (2H, s), 3.50 (1H, m), 3.20 (2H,
30 s), 2.80-2.65 (4H, m), 2.20-1.20 (16H, m).

Similarly prepared were:

EXAMPLE 2

2-(2-Chloro-benzothiazol-6-yl)-N-(1-cyclooct-1-enylmethyl-piperidin-4-yl)-acetamide

From (2-chloro-benzothiazol-6-yl)acetic acid (77 mg) and Intermediate 1 as an off white solid. $R_f = 0.375$ (10% MeOH, DCM); MS 432, 434 (M+H).

EXAMPLE 3

2-(5-Chloro-benzo[b]thiophen-3-yl)-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide

From 5-chlorobenzo[b]thiophene-3-acetic acid (78 mg) and Intermediate 1 as an off white solid. $R_f = 0.44$ (10% MeOH, DCM); MS 431, 433 (M+H).

EXAMPLE 4

N-(1-cyclooct-1-enylmethylpiperidin-4-yl)-2-(2-methylsulfanylbenzoxazol-5-yl)-acetamide

From Intermediate 2 (75 mg) and Intermediate 1 as a pale yellow solid. $R_f = 0.375$ (10% MeOH, DCM); MS 428 (M+H).

EXAMPLE 5

2-Benzofuran-3-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide

From Intermediate 4 (66 mg) and Intermediate 1 as an off-white solid $R_f = 0.11$ (5% MeOH/DCM); MS 381 (M+H).

EXAMPLE 6

3-Benzofuran-4-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)propionamide

From intermediate 5 (110 mg) and Intermediate 1 as a glassy solid $R_f = 0.28$ (7% MeOH/DCM); MS 395 (M+1).

EXAMPLE 7

N-(1-Cyclooct-1-enylmethylpiperidine-4-yl)-2-(1-methyl-1H-indol-3-yl)acetimidate

From 3-(N-methylindole)-acetic acid (32 mg) and Intermediate 1 as a off-white solid $R_f = 0.40$ (10% MeOH/DCM); MS 394 (M+H).

EXAMPLE 8

5 **2-Benzothiophen-3-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide**

From intermediate 6 (65 mg) and Intermediate 1 as a tan solid $R_f = 0.45$ (10% MeOH/DCM); MS 397 (M+H); δH (CDCl₃) 7.87-7.93 (1H, m), 7.70-7.77 (1H, m), 7.36-7.43 (2H, m), 7.34 (1H, s), 5.44 (1H, t), 5.33 (1H, bd), 3.80 (2H, s), 3.73-3.87 (1H, m), 2.75 (2H, s), 2.55-2.70 (2H, m), 2.04-2.19 (4H, m), 1.90-2.04 (2H, m), 1.72-1.83 (2H, m), 1.37-1.70 (8H, m), 1.20-1.35 (2H, m).

Example 9

3-Benzo[b]thiazol-2-yl-N-(cyclooct-1-enylmethylpiperidin-4-yl)propionamide

15 From 3-(benzo[b]thiazol-2-yl)propionic acid (35 mg) and Intermediate 1 as a colourless oil. $R_f = 0.37$ (10% MeOH/DCM); MS 412 (M+H).

Example 10

2-Benzofuran-2-yl-N-(1-cyclooct-1-enylmethyl-piperidin-4-yl)acetamide

20 From 2-(benzofuran-2-yl)acetic acid (CAS No 62119-70-4, 100 mg) and Intermediate 1 as a colourless oil $R_f = 0.53$ (15% MeOH/DCM); MS 381 (M+H).

EXAMPLE 11

25 **4-(2-Benzofuran-4-yl-ethanoylamino)-1-cyclooct-1-enylmethyl-1-ethyl-piperidinium iodide**

The compound of Example 1 (71 mg) and iodoethane (5 ml) were combined and heated to 75° for 70h. The reaction mixture was evaporated *in vacuo* to give the title compound as a brown solid (mixture of *trans/cis* isomers; ratio 5:1). MS 409 (M+ for salt); δH (CDCl₃) major isomer: 8.00-7.90 (1H, br s), 7.60-7.00 (5H, m), 6.00 (1H, t), 4.30-3.10 (11H, m), 2.50-1.20 (19H, m).

Example 12**2-Benzofuran-4-yl-N-[1-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]acetamide**

- 5 Intermediate 8 (100 mg), (1R)-(-) myrtenal (0.052 ml), triethylamine (0.05 ml) and powdered molecular sieves (4Å) were combined in tetrahydrofuran (10 ml) under nitrogen. The reaction mixture was stirred for 30 min before addition of sodium triacetoxyborohydride (144 mg). After stirring for 20 h the reaction was quenched by addition of sat. NaHCO₃ and extracted with DCM (3x20 ml). The
- 10 combined organic extracts were washed with brine (20 ml), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash chromatography gave the title compound as a white solid (68 mg). R_f = 0.22 (5% MeOH/ DCM); δH (CDCl₃) 7.70 (1H, d), 7.52 (1H, d), 7.40 (1H, d), 7.12 (1H, m), 6.85 (1H, m), 5.36 (1H, m), 5.28 (1H, m), 3.83 (2H, s), 3.80-3.68 (1H, m), 2.89-2.62 (4H, m), 2.40-2.24
- 15 (4H, m), 2.15-1.95 (4H, m), 1.89-1.80 (3H, m), 1.38-1.19 (2H, m), 1.30 (3H, s), 1.08 (1H, d), 0.80 (3H, s); MS 393 (M+H).

Similarly prepared were:

20 **Example 13**

2-Benzofuran-4-yl-N-[1-(2-ethyl-hex-2-enyl)piperidin-4-yl]acetamide

From 2-ethyl-2-hexenal (43 mg) and Intermediate 8 as a colourless oil. R_f = 0.16 (5% MeOH/ DCM); MS 369 (M+H).

25 **Example 14**

2-Benzofuran-4-yl-N-[1-(3,5,5-trimethylhexyl)piperidin-4-yl]acetamide

From 3,5,5-trimethylhexanal (0.088 ml) and Intermediate 8 as a white solid R_f = 0.37 (10% MeOH/DCM); MS 385 (M+H).

30 **Example 15**

2-Benzofuran-4-yl-N-[1-((S)-6,6-Dimethyl-bicyclo[3.1.1]hept-2-ylmethyl)piperidin-4-yl]acetamide

From (1S, 2S, 5S)-(-)-myrtanal (CAS No 128301-02-01, 77 mg) and Intermediate 8 as a white solid R_f 0.48 (10% MeOH/DCM); MS 395 (M+H).

Example 16**2-Benzofuran-4-yl-N-[1-(2-cyclohexylpropyl)piperidin-4-yl]acetamide**

From Intermediate 9 (73 mg) and Intermediate 8 as a white solid (107 mg).

R_f = 0.50 (10% MeOH/DCM); δH ($CDCl_3$) 7.65 (1H, d), 7.50 (1H, d), 7.25 (1H, d), 7.05 (1H, d), 6.80 (1H, d), 5.35 (1H, br d), 3.85-3.70 (3H, m), 3.50 (2H, s), 2.85-2.60 (2H, m), 2.30-0.90 (18H, m), 0.80 (3H, d); MS 383.4 (M+H).

Example 17**2-Benzofuran-4-yl-N-[1-(5-fluoro-2,3-dihydrobenzofuran-2-yl)methyl]****piperidin-4-yl]acetamide**

Intermediate 8 (0.14 g) was partitioned between DCM (3x10 ml) and 1M sodium hydroxide (20 ml). The organic phase was washed with brine (20 ml), dried ($MgSO_4$) and concentrated *in vacuo* to give the amine free base for use in the following reaction:

2-Benzofuran-4-yl-N-piperidin-4-ylacetamide (122 mg), 2-bromomethyl-5-fluorocoumaran (100 mg), triethylamine (0.10 ml) and tetrabutylammonium iodide (10 mg) were combined in DMF (5 ml) under nitrogen. The reaction mixture was stirred for 60h, diluted with DCM (25 ml) and washed with H_2O (4x10 ml) and brine (10 ml), dried ($MgSO_4$) and evaporated *in vacuo*. Purification by flash chromatography gave the title compound as a yellow solid (60 mg). R_f = 0.16 (5% MeOH, CH_2Cl_2); δH ($CDCl_3$) 7.68 (1H, m), 7.48 (1H, m), 7.30 (1H, m), 7.10 (1H, m), 6.88-6.72 (3H, m), 6.65 (1H, m), 5.22 (1H, m), 4.90-4.80 (1H, m), 3.80 (2H, m), 3.25-3.15 (1H, m), 2.92-2.65 (3H, m), 2.50-2.42 (1H, m), 2.20-2.10 (2H, m), 1.85-1.78 (4H, m), 1.30-1.22 (2H, m). MS 409 (M+H).

Similarly prepared was:

Example 18**2-Benzofuran-4-yl-N-[1-(2-phenoxyethyl)piperidin-4-yl]acetamide**

From β -bromophenetole (75mg) and 2-benzofuran-4-yl-N-piperidin-4-ylacetamide as a white solid R_f 0.2 (15% MeOH/DCM) MS 379 (M+H)

Example 19**2-Benzofuran-4-yl-N-[1-(3-phenylpropyl)piperidin-3-yl]acetamide**

Intermediate 11 (132 mg), 3-phenylpropionaldehyde (0.1 ml) and triethylamine (0.07 ml) were combined in tetrahydrofuran (10 ml) under nitrogen. The
5 reaction mixture was stirred for 10min before addition of sodium triacetoxymethylborohydride (293 mg). After stirring for 20h the reaction was quenched by addition of 1M NaOH (30 ml) and extracted with DCM (3x20 ml). The combined organic extracts were washed with brine (20 ml), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash chromatography gave the title
10 compound as a white solid (90 mg).

R_f = 0.48 (10% MeOH, DCM); δ H (CDCl₃) 7.55 (1H, d), 7.40-7.00 (7H, m), 6.80 (1H, s), 6.15 (1H, br s), 4.05 (1H, br s), 3.80 (2H, s), 2.50-1.90 (6H, m), 1.80-1.20 (9H, m); MS 377.3 (MH⁺).

Example 20**2-Benzofuran-4-yl-N-(1-benzylpiperidin-4-yl)acetamide**

2-(1-Benzofuran-4-yl)acetic acid (500 mg), EDC.HCl (814 mg), 4-amino-N-benzylpiperidine (0.58 ml), DMAP (10 mg), and DCM (50 ml) were combined
under a nitrogen atmosphere and stirred at RT for 16h. The reaction mixture
20 was then diluted with DCM (50 ml), washed with 1N aqueous NaOH solution (40 ml), brine (40 ml) and evaporated *in vacuo*. Purification by flash chromatography gave the title compound as a white solid (950 mg). R_f = 0.31 (10% MeOH, DCM); δ H (CDCl₃) 7.65 (1H, d), 7.48 (1H, d), 7.38-7.25 (6H, m), 7.19 (1H, d), 6.80 (1H, d), 5.30-5.25 (1H, m), 3.85-3.78 (3H, m), 3.48 (2H, s),
25 2.82-2.70 (2H, m), 2.15-2.10 (2H, m), 1.96-1.80 (2H, m), 1.40-1.30 (2H, m); MS 349 (M+H).

EXAMPLE 21**3-Benzofuran-2-yl-N-[1-(3,4-dichlorobenzyl)piperidin-4-yl]propionamide**

30 3-(Benzofuran-2-yl)propionic acid (CAS No 21683-86-3, 612 mg) in DCM (10 ml) was treated with oxalyl chloride (0.56 ml) and DMF (1 drop). The mixture was stirred for 18 hrs and the solvents were removed *in vacuo*. The residue was dissolved in DCM (10 ml) and 1-(3,4-dichlorobenzyl)piperidin-4-ylamine dihydrochloride (CAS No 57645-61-1, 834mg) and triethylamine (1.4

ml) was added. The mixture was stirred for 1.5 hr before diluting with DCM and washed with 1N aqueous NaOH solution (20 ml) and evaporated *in vacuo* onto silica. Purification by flash chromatography gave the title compound as an off white solid. $R_f = 0.45$ (10% MeOH/DCM); δH ($CDCl_3$) 7.50-7.10 (7H, m), 6.40 (1H, s), 5.35 (1H, d), 3.90-3.70 (1H, m), 3.35 (2H, s), 3.10 (2H, t), 2.70-2.55 (4H, m), 2.10 (2H, t), 1.85 (2H, d), 1.45-1.20 (2H, m); MS 432 (M+H).

Example 22

2-Benzofuran-4-yl-N-[1-(3-phenylpropyl)piperidin-4-yl]acetamide

Intermediate 8 (100 mg), 3-phenylpropionaldehyde (0.05 ml), triethylamine (0.05 ml) and powdered molecular sieves (4Å) were combined in tetrahydrofuran (10 ml) under nitrogen. The reaction mixture was stirred for 30min before addition of sodium triacetoxyborohydride (144 mg). After stirring for 20h the reaction was quenched by addition of sat. $NaHCO_3$ and extracted with DCM (3x20 ml). The combined organic extracts were washed with brine (20 ml), dried ($MgSO_4$) and evaporated *in vacuo*. Purification by flash chromatography gave the title compound as a white solid (97 mg). $R_f = 0.29$ (10% MeOH, CH_2Cl_2); δH ($CDCl_3$) 7.67 (1H, m), 7.48 (1H, d), 7.28 (3H, m), 7.10 (4H, m), 6.80 (1H, m), 5.26 (1H, d), 3.78 (3H, m), 2.75 (2H, m), 2.60 (2H, m), 2.30 (2H, m), 2.10-2.00 (2H, m), 1.83-1.72 (4H, m), 1.35-1.22 (2H, m). MS 377 (M+H).

Similarly prepared were:

Example 23

2-Benzofuran-4-yl-N-[3,4-dichlorobenzyl]piperidin-4-yl]acetamide, formate salt

From 3,4-dichlorobenzaldehyde (89 mg) and Intermediate 8 with purification by reverse phase preparative HPLC using a 25cm x 21.2mm Phenomenex Luna C18 (2) (5u) column and a mobile phase of aqueous formic acid (0.1% v/v) and acetonitrile under gradient conditions from 5% to 75% acetonitrile. The title compound was obtained as a white solid. R_f 0.47 (10% MeOH/DCM); MS 418 [(M+H)-formate].

Example 24**2-Benzofuran-4-yl-N-[1-[3-(3,4-dichloro-phenyl)-propyl]-piperidin-4-yl]-acetamide**

From Intermediate 14 (142 mg) and Intermediate 8 as a white solid (130 mg).

- 5 $R_f = 0.13$ (10% MeOH, 89% DCM, 1% $\text{NH}_{3(\text{aq.})}$). δH (CDCl_3) 7.65 (1H, d), 7.45 (1H, d), 7.2.35-7.15 (3H, m), 7.10 (1H, d), 6.95 (1H, d), 6.80 (1H, d), 5.25 (1H, br d), 3.85-3.70 (3H, m), 2.65 (2H, br d), 2.55 (2H, t), 2.25 (2H, t), 2.00 (2H, t), 1.85-1.55 (4H, m), 1.35-1.15 (2H, m), MS 445.3 (M+H).

10 **Example 25**

2-Benzofuran-4-yl-N-[1-(2-methyl-3-phenyl-propyl)-piperidin-4-yl]-acetamide

From Intermediate 15 (40 mg) and Intermediate 8 as a white solid (40 mg). R_f

- 15 $= 0.37$ (10% MeOH, DCM); δH (CDCl_3) 7.65 (1H, d), 7.40 (1H, d), 7.20-7.15 (5H, m), 7.10 (2H, d), 6.80 (1H, d), 5.25-5.15 (1H, m), 3.80 (2H, s), 2.80-2.50 (3H, m), 2.30-2.20 (1H, m), 2.15-1.70 (6H, m), 1.35-1.15 (3H, m), 0.80 (3H, d); MS 391.4 (M+H).

- 20 The following assays were used to demonstrate the potency and selectivity of the compounds according to the invention for inhibition of chemokine binding to CCR-3 receptors.

CCR-3 calcium assay


- 25 The following assay was performed using a FLIPR.

- CHO cells stably transfected with CCR-3 were used in the assay. These were routinely passaged in RPMI 1640 with glutamine, non-essential amino-acids, 10% FCS and 0.4mg/ml G-418 (the selection agent) at 37° with 5% CO_2 . the cells were removed from the culture flask using non-enzymatic dissociation agent, washed, resuspended at $1.5 \times 10^5/\text{ml}$ in medium, dispensed into black-walled, clear-bottomed tissue culture plates at 200 μl /well and incubated overnight. The culture medium was replaced with 100 μl /well dye loading
- 30

buffer (HBSS, 0.2% BSA, 1mM probenecid, 4 μ M Fluo-4 and 0.08% pluronic acid). After 1-2h incubation the loading buffer was removed and the plate washed leaving 100 μ l/well of wash buffer (HBSS, 0.2% BSA, 1mM probenecid). Compounds were dissolved in DMSO then diluted 1:125 in wash
5 buffer. The FLIPR was programmed to add diluted compound and after 2 mins diluted human recombinant eotaxin (final concentration of 10nM). Inhibition was calculated as a function of maximum calcium response.

CLAIMS

1. A compound of formula (1):




5

wherein:

q is zero or the integer 1, 2 or 3;

- R which when present may be attached to any available carbon or nitrogen atom of the bicyclic heteroaromatic ring of formula (1) is an atom or group –
- 10 $L^3(Alk^3)_wL^4(R^8)_u$ in which L^3 and L^4 which may be the same or different is each a covalent bond or a linker atom or group, w is zero or the integer 1, u is the integer 1, 2 or 3, Alk^3 is an optionally substituted aliphatic or heteroaliphatic chain and R^8 is a hydrogen or halogen atom or a group selected from alkyl, –
- 15 OR^9 [where R^9 is a hydrogen atom or an optionally substituted alkyl group], – SR^9 , – NR^9R^{10} , [where R^{10} is as just defined for R^9 and may be the same or different], – NO_2 , – CN , – CO_2R^9 , – OCO_2R^9 , – $CONR^9R^{10}$, – $OCONR^9R^{10}$, – $CSNR^9R^{10}$, – COR^9 , – $OCOR^9$, – $N(R^9)COR^{10}$, – $N(R^9)CSR^{10}$, – $SO_2N(R^9)(R^{10})$, – $N(R^9)SO_2R^{10}$, – $N(R^9)CON(R^{10})(R^{11})$, [where R^{11} is a hydrogen atom or an optionally substituted alkyl group], – $N(R^9)CSN(R^{10})(R^{11})$, –
- 20 $N(R^9)SO_2N(R^{10})(R^{11})$ or an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group provided that when w is zero and each of L^3 and L^4 is a covalent bond then u is the integer 1; or
- when q is the integer 2 or 3 and two R groups are attached to adjacent carbon atoms of the heteroaromatic ring of formula (1) these may be joined
- 25 together with the heteroaromatic ring carbon atoms to form an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;
- X is an O atom or a $S(O)_m$ atom or group in which m is zero or the integer 1 or 2 or an NR group;
- 30 Y is a N atom or a CR^{1a} group in which R^{1a} is a group R or a group R^1 ;

R^1 which may be on any available carbon atom of the bicyclic heteroaromatic ring of formula (1) is a hydrogen atom or a group $-Alk^1L^1CyAlk^2L^2D$ in which Alk^1 is an optionally substituted C_{1-3} alkyl group, Alk^2 is an optionally substituted aliphatic or cycloaliphatic group, L^1 is a $-CON(R^5)-$, $-N(R^5)CO-$, $-SO_2N(R^5)-$ or $-N(R^5)SO_2-$ group in which R^5 is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group, L^2 is a covalent bond or an $-O-$ atom or $-S(O)_n-$ atom or group in which n is zero or the integer 1 or 2 or $-N(R^7)-$ group in which R^7 is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group, D is an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group and Cy is an optionally substituted heterocycloaliphatic ring of formula (A) or (B):




in which

a indicates the point of attachment of any available ring carbon in the ring Cy to the group L^1 , b indicates the point of attachment to Alk^2 , s and t which may be the same or different is each zero or the integer 1 or 2, provided that $s + t$ is the integer 1, 2, 3 or 4, R^6 is an optionally substituted alkyl group and X is a pharmaceutically acceptable counterion; provided that at least one but not both of R^1 and R^{1a} is the group $-Alk^1L^1CyAlk^2L^2D$; and the salts, solvates, hydrates, N-oxides thereof.

2. A compound of Claim 1, wherein X is an O or S atom or a NR^2 group, where NR^2 is a NH, NCH_3 or NCH_2Ph group, where Ph is an optionally substituted phenyl ring.

3. A compound according to Claim 2, wherein X is an oxygen atom.

4. A compound according to Claims 1-3 of formula (2):



(2)

5 wherein the numbers 1 to 7 indicate the atom numbering of the heteroaromatic ring according to IUPAC nomenclature and R, q, R¹, R¹a and X are as generally and particularly defined herein for compounds of formula (1); and the salts, solvates, hydrates, N-oxides thereof.

10 5. A compound according to Claims 1-4 wherein R¹a is a group Alk¹L¹CyAlk²L²D.

6. A compound according to Claims 1-4 wherein R¹ is a group -Alk¹L¹CyAlk²L²D and R¹a is an atom or group R.

15

7. A compound according to Claim 6 wherein R¹ is attached to the carbon atom numbered 4.

8. A compound according to any preceding Claim wherein q is zero or the integer 1 or 2, preferably zero.

9. A compound according to any preceding Claim wherein Alk¹ in the substituent -Alk¹L¹CyAlk²L²D is an optionally substituted -CH₂- or -CH₂CH₂-group.

25

10. A compound according to any preceding Claim wherein L¹ in the substituent -Alk¹L¹CyAlk²L²D is a -CON(R⁵)- group.

11. A compound according to any preceding Claim wherein R¹ or the group R¹a is the group -Alk¹L¹CyAlk²L²D in which L¹ is the group -CON(R⁵)-

30

in which R^5 is a hydrogen atom or $-CH_3$ or $-CH_2CH_3$ group, L^2 is a covalent bond and Alk^2 is an optionally substituted $-CH_2-$, $-CH(CH_3)-$ or $-CH_2CH_2-$ group.

12. A compound according to any preceding Claim wherein s and t in the heterocycloaliphatic ring Cy are each the integer 1.

13. A compound according to any preceding Claim wherein D is an optionally substituted C_{3-8} cycloalkyl or C_{3-8} cycloalkenyl group.

10

14. A compound which is:

2-benzofuran-4-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide;

2-(2-chloro-benzothiazol-6-yl)-N-(1-cyclooct-1-enylmethyl-piperidin-4-yl)-acetamide;

15 2-(5-chloro-benzo[b]thiophen-3-yl)-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide;

N-(1-cyclooct-1-enylmethylpiperidin-4-yl)-2-(2-methylsulfanylbenzoxazol-5-yl)-acetamide;

4-(2-benzofuran-4-yl-ethanoylamino)-1-cyclooct-1-enylmethyl-1-ethyl-

20 piperidinium iodide;

and the salts, solvates, hydrates and N-oxides thereof.

15. A compound which is:

2-benzofuran-3-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide;

25 3-benzofuran-4-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)propionamide;

N-(1-cyclooct-1-enylmethylpiperidine-4-yl)-2-(1-methyl-1*H*-indol-3-yl)acetimidate;

2-benzothiophen-3-yl-N-(1-cyclooct-1-enylmethylpiperidin-4-yl)acetamide;

3-benzo[b]thiazol-2-yl-N-(cyclooct-1-enylmethylpiperidin-4-yl) propionamide;

30 2-benzofuran-2-yl-N-(1-cyclooct-1-enylmethyl-piperidin-4-yl)acetamide;

2-benzofuran-4-yl-N-[1-(6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]acetamide;

2-benzofuran-4-yl-N-[1-(2-ethyl-hex-2-enyl)piperidin-4-yl]acetamide;

2-benzofuran-4-yl-N-[1-(3,5,5-trimethylhexyl)piperidin-4-yl]acetamide;

- 2-benzofuran-4-yl-N-[1-((S)-6,6-dimethyl-bicyclo[3.1.1]hept-2-ylmethyl)
piperidin-4-yl]acetamide;
2-benzofuran-4-yl-N-[1-(2-cyclohexylpropyl)piperidin-4-yl]acetamide;
2-benzofuran-4-yl-N-[1-(5-fluoro-2,3-dihydrobenzofuran-2-ylmethyl) piperidin-4-
5 yl]acetamide;
2-benzofuran-4-yl-N-[1-(2-phenoxyethyl)piperidin-4-yl]acetamide;
2-benzofuran-4-yl-N-[1-(3-phenylpropyl)piperidin-3-yl]acetamide;
2-benzofuran-4-yl-N-(1-benzylpiperidin-4-yl)acetamide;
3-benzofuran-2-yl-N-[1-(3,4-dichlorobenzyl)piperidin-4-yl]propionamide;
10 2-benzofuran-4-yl-N-[1-(3-phenylpropyl)piperidin-4-yl]acetamide;
2-benzofuran-4-yl-N-[3,4-dichlorobenzyl)piperidin-4-yl]acetamide, formate salt;
2-benzofuran-4-yl-N-{1-[3-(3,4-dichloro-phenyl)-propyl]-piperidin-4-yl}-
acetamide;
2-benzofuran-4-yl-N-[1-(2-methyl-3-phenyl-propyl)-piperidin-4-yl] acetamide;
15 and the salts, solvates, hydrates and N-oxides thereof.

16. A pharmaceutical composition comprising a compound according to
Claim 1, together with one or more pharmaceutically acceptable carriers,
excipients or diluents.

20

17. Use of a compound of Claim 1, for the manufacture of a medicament
for the treatment of immune or inflammatory disorders.

25

30

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/GB 01/03721

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D405/12 C07D419/12 C07D417/12 A61K31/34 A61K31/445 A61P37/00 A61P29/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, EPO-Internal, PAJ, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 53600 A (BANYU PHARMA CO LTD ;KOBAYASHI KENSUKE (JP); ISHIKAWA MAKOTO (JP);) 14 September 2000 (2000-09-14) * see the definition R3,R4 = H * the whole document	1-17
Y	WO 00 35876 A (DU PONT PHARM CO) 22 June 2000 (2000-06-22) * see p.117, cores a,b,c, exs. with R5 = CH2-phenyl * the whole document	1-17
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search 21 November 2001		Date of mailing of the international search report 29/11/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Stellmach, J

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/GB 01/03721

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SAUNDERS J ET AL: "OPPORTUNITIES FOR NOVEL THERAPEUTIC AGENTS ACTING AT CHEMOKINE RECEPTORS" DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 4, no. 2, February 1999 (1999-02), pages 80-92, XP000882226 ISSN: 1359-6446 * see p.91, fig. 10 * the whole document</p>	1-17
A	<p>WO 98 22452 A (OHSHIMA ETSUO ; ICHIMURA MICHIO (JP); IIDA KYOICHIRO (JP); MATSUZAK) 28 May 1998 (1998-05-28) the whole document</p>	1-17
A	<p>DE 27 30 593 A (DELALANDE SA) 19 January 1978 (1978-01-19) the whole document</p>	1-17

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Present claims 1-9 relate to an extremely large number of possible compounds. In fact, the claims refer to such an enormous amount of compounds which contain so many structural options, variables, possible permutations and provisos and which contain only a minor fixed part (structural isomerism, compare in particular the structural possibilities of the linking of the 2 aromatic/hetero aromatic groups R1 and R) and a large number of variables which themselves may contain variables (compare in particular R, R1 and D') that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely claims 10 - 15 and 1 - 9, 16 and 17 partially e.g. those compounds recited in the examples and closely related homologous compounds (see in the description at page 21 given in Formula (1) and (2) in combination with the limitation given in claims 2-9 .

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No
PCT/GB 01/03721

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0053600	A	14-09-2000	AU 2942000 A WO 0053600 A1	28-09-2000 14-09-2000
WO 0035876	A	22-06-2000	AU 2056700 A EP 1140833 A1 WO 0035876 A1	03-07-2000 10-10-2001 22-06-2000
WO 9822452	A	28-05-1998	AU 4967797 A WO 9822452 A1	10-06-1998 28-05-1998
DE 2730593	A	19-01-1978	FR 2358143 A1 FR 2396008 A2 AU 516331 B2 AU 2695477 A BE 856296 A1 CA 1100958 A1 CH 625234 A5 CH 630621 A5 CH 627175 A5 DE 2730593 A1 ES 460600 A1 ES 470783 A1 ES 470784 A1 GB 1545725 A GR 61634 A1 IT 1115363 B JP 1303577 C JP 54012365 A JP 60028831 B LU 77713 A1 MX 7132 E MX 5083 E NL 7707713 A SE 441268 B SE 7708041 A SE 8300445 A SE 8300446 A SU 655312 A3 SU 778710 A3 SU 747425 A3 US 4113951 A US 4153620 A ZA 7704067 A JP 1339955 C JP 58213770 A JP 61006070 B	10-02-1978 26-01-1979 28-05-1981 18-01-1979 30-12-1977 12-05-1981 15-09-1981 30-06-1982 31-12-1981 19-01-1978 01-12-1978 01-09-1979 16-01-1979 16-05-1979 04-12-1978 03-02-1986 28-02-1986 30-01-1979 06-07-1985 31-01-1978 28-07-1987 14-03-1983 16-01-1978 23-09-1985 13-01-1978 28-01-1983 28-01-1983 30-03-1979 07-11-1980 23-07-1980 12-09-1978 08-05-1979 30-05-1978 29-09-1986 12-12-1983 24-02-1986

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.